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Abstract
Identifying biomarkers that can be used to classify certain disease stages or predict
when a disease becomes more aggressive is one of the most important applications of
machine learning. Next generation sequencing (NGS) is a state-of-the-art method that
enables fast sequencing of DNA or RNA samples. The output usually contains a very
large file that consists of base pairs of DNA or RNA. The generated data can be analyzed
to provide gene expression, chromosome counting, detection of mutations on the genes,
and detecting levels of copy number variations or alterations in specific genes, just as
examples. NGS is leading the way to explore the human genome, enabling the future of
personalized medicine. In this thesis, a demonstration is done on how machine learning is
used extensively to identify genes that can be used to predict prostate cancer stages with
very high accuracy, using gene expression. We have also been successful in predicting the
location of prostate tumors based on gene expression.
In addition, traditional biomarker identification approaches, typically, use ma-
chine learning techniques to identify a number of genes and macromolecules as biomarkers
that can be used to diagnose specific diseases or states of diseases with very high accuracy,
using molecular measurements such as mutations, gene expression, copy number varia-
tions, and others. However, experts’ opinions and knowledge is required to validate such
findings. We, therefore, also introduce a new machine learning model that incorporates
a knowledge-assisted system used to integrate the findings of the DisGeNET database,
which is a framework that contains proven relationships among diseases and genes. The
machine learning pipeline starts by reducing the number of features using a filter-based
VI
feature selection method. The DisGeNET database is used to score each gene related to
the given cancer name. Then, a wrapper-based feature-selection algorithm picks the best
set of genes with the highest classification accuracy. The method has been able to re-
trieve key genes from multiple data sets that classify with very high accuracy, while being
biologically relevant, and no human intervention needed. Initial results provide a high
area-under-the-curve with a handful of genes that are already proven to be related to the
relevant disease and state based on the latest published medical findings. The proposed
methods results provide biomarkers that can be verified in wet lab environments and can
then be further analyzed and studied for diagnostic purposes.
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Machine learning provides tools and methods that help work on large data sets to find
patterns that are usually hidden. The main idea behind machine learning is that we do
not explicitly provide the rules, but examples of the data and the labels associated with it
[1]. As such, the underlying algorithms will be able discover the hidden patterns and rules
that can be used to predict the class labels for a new, unknown sample [2]. The methods
used for of automatic classification and recognition of newly given samples are becoming
very important and are used in many fields, including the fields of biology and clinical
diagnosis.
Cancer is one of the main causes of death worldwide. Cancer is considered a
genetic disorder [3], in which gene mutations and changes cause the cells to malfunction,
which affects the cells growth and division. Roughly speaking, genes are “transformed” into
proteins that are responsible for most of the work in biological processes and are required
1
Figure 1.1: The central dogma of molecular biology.
for the structure, function, and regulation of the body’s tissues and organs. Parts of the
DNA are transcribed into messenger RNA (mRNA) through the process of transcription
and then they will be translated into proteins in the process of translation. The full process
is typically called the central dogma and is illustrated in Figure 1.1 Changes to the genes,
mRNAs or the proteins may lead to some kind of malfunctions in the cell or tissue. As
such, tissue might then go through uncontrolled growth and become cancer.
1.1 Prostate cancer
Prostate cancer is the cancer type with the highest incidence among males; around 1.276
million cases were newly diagnosed worldwide in 2019 [1]. In prostate cancer, the size
of the main tumour and the lymphatic involvement are used to assign a metric of tissue
organization and disease aggressiveness called the Gleason score.
The Gleason score is calculated by adding two numbers: the most common pattern
2
Table 1.1: Gleason groups as per the latest study from Epstein et al [4].
Gleason Group Score
1 6
2 3 + 4 = 7
3 4 + 3 = 7
4 8
5 9 and 10
of the tumour cells is used as the first number, while the second number corresponds to
the next most common pattern. Each individual score varies from 3 to 5, depending on
the aggressiveness of the tumour. This number is determined by a pathologist, where the
highest score means the most aggressive form of cancer [4]. For example a Gleason score
of 3+3=6 is the first stage of prostate cancer, while a 5+5=10 is considered the last stage
of the disease. Epstein et al., however, indicated that Scores 2–5 are no longer assigned to
the tissue and these multiple scores can be categorized together with score 6 as group 1,
yielding categories as depicted in Table 1.1.
Prostate cancer tumor can be located in three different locations, left, right or
the middle of the prostate gland. A recent study by Akatsuka et al. [6] concluded that
cancer incidence and prognosis varies based on the location within the prostate gland. In
Chapter 3 we utilized gene expressions to predict the location of the tumor.
1.2 Next Generation Sequencing
The first successful attempts to sequence DNA started in the early 1970s by academic
researchers using laborious methods based on two-dimensional chromatography. Then,
3
Figure 1.2: Illumnia Nextseq 550 model is one of the most powerful next generation se-
quencers; image taken from the Illumina website [9]
fluorescence-based sequencing methods were developed with a DNA sequencer [7]. The
whole process of DNA sequencing became much easier and faster in the late 2000s [8].
Since then, DNA sequencing technology speeds increased dramatically, which
cleared the way to start the process of sequencing the complete DNA of different species of
life, including the Human genome. Next generation sequencing (NGS) parallel processing
power enabled the sequencing of a massive number of DNA molecules at the same time,
whose number can stretch up to the order of millions of molecules.
The high-throughput and the possibility of sequencing multiple samples in the
same run enabled researchers to advance in the fields of clinical diagnostics, personalized
medicine and genetic diseases, among others. Modern-day Sanger sequencing instruments
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use capillary-based automated electrophoresis, which typically analyzes 8–96 sequencing
reactions simultaneously. NGS systems have been introduced in the past decade, allowing
for massively parallel sequencing reactions. These systems are capable of analyzing millions
or even billions of sequencing reactions at the same time. The major disadvantage of this
technology is that to achieve a significant level of accuracy very short sequencing reads
have to be generated.
These include whole genome sequencing, exome sequencing, RNA sequencing,
disease panels, lane rentals, and many more. Illumina is one of the market leaders in pro-
viding life science tools and integrated systems for large-scale analysis of genetic variation
and function. They produce multiple models of next generation sequencers, such as the
Illumina Nextseq 550 sequencer model shown in Figure 1.2.
1.3 Gene Expression Data Analysis and Machine Learn-
ing Methods
The data produced by NGS are usually large raw data sets, which may include the whole
genome DNA or messenger RNA from the tissues that are inspected. These raw data sets
consist of millions of short sequence reads, which are used to measure gene expression at
the nucleotide resolution level. The first step to obtain information from thes data consists
of aligning these reads to a reference genome. There are many tools that can be used to
perform this task. One of the most widely-used tools is Tophat2 [10], which aligns the
given raw reads into annotated genes or transcripts. STAR [11] is another aligner tool
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that is well-known for its blazing aligning speed. The next step involves counting these
reads. This task can be done using tools like Tophat2 or RSEM [12] to generate the “gene
expressions”, which are accounted for in terms of TPM (Transcripts Per Kilobase Million).
Figure 1.3 shows the pipeline used to obtain the TPM expression levels from the raw reads
that the NGS technology produces.
Once we obtain the gene expressions from each sample and the label of the cor-
responding sample, the next step is a direct implementation of machine learning methods.
Machine learning provides methods to handle data with given labels, which are
called supervised learning. We also have unsupervised learning methods which deals with
data without labels. Classifiers are methods that can utilize data that includes features
and their corresponding labels to build a model that is capable of predicting the labels
of new given, unlabelled samples. For example, a sample has gene expressions which are
considered features and also has a Gleason score that can be considered the label.
There are many classifiers that can be used, but there is no specific classifier
that can solve all the problems efficiently. In Chapter 2, we used multiple classifiers to
build a model that predicts the Gleason group of a sample prostate tumour given it’s gene
expressions, while in Chapter 3, we used different classifiers to predict the location of the
tumour.
The data generated from the NGS includes gene and transcript data for each
sample. A single sample can contain up to 70,000 transcripts or more than 30,000 genes.
Dealing with this huge number of features would make the classifiers struggle with pro-
cessing all the features; this problem is known as the curse of dimensionality. Machine
6
Figure 1.3: Pipeline used to obtain the TPM expression levels from the raw reads that the
NGS technology produces.
7
learning has tools to reduce the number of features using feature selection methods.
1.4 Traditional and Integrative Machine Learning Fea-
ture Selection Methods
Traditional feature selection is generally done in two steps. The initial step involves filter-
based the feature selection, which aims at giving a score to each feature based on its effect
on the predicted target for the main classifier. Each attribute, which in our case, are
the genes, is assigned a score that depends on how relevant the feature is to perform the
classification task. The second step is a wrapper-based feature selection method, which
involves identifying sets of attributes that can be used to categorize certain biological
features (the target) [13]. An example of a clinical feature that can be used as a target for
classification is the Gleason score in prostate cancer or progression stages in breast cancer.
The constructed model can then be assessed using certain performance measures, such as
accuracy, specificity, or Area Under the Receiver Operating Characteristics (AUC-ROC)
[14].
The final step of traditional machine learning entails a trained individual deter-
mining the validity of the results based on the newest literature.
In order to evaluate the model, certain metrics are used, such as accuracy which
calculates the ratio of correctly classified samples against the total number of samples [15].
Another two metrics used are sensitivity and specificity, where sensitivity indicates, how
well the test predicts one category and specificity measures how well the test predicts the
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other category. Another important metric is the AUC (Area Under The Curve), where the
curve is the ROC (Receiver Operating Characteristics) curve. It is a graph that shows the
performance of a classification model by plotting the True Positive Rate (TPR) against the
False Positive Rate (FPR), where TPR is the the number of samples classified correctly
as a positive class divided by the sum of both the number of samples classified incorrectly
as the negative class and number of samples classified correctly as the positive class. FPR
is the number of samples classified correctly as a negative class divided by the sum of
both the number of samples classified incorrectly as the negative class and the number
of samples classified correctly as the positive class. This area indicates the capability of
the model to distinguish between different classes. A higher AUC value means a better
predictive model.
On the other hand, integrative techniques add domain knowledge from trusted
external knowledge databases during feature selection, which might lead to better ability to
interpret the data and might give a better predictive outcome. A recent study by Perscheid
et al. proposed a framework that utilizes domain knowledge from different databases to
generate a list of genes related to the disease of study [16].
The way genes affect certain diseases is an area that is being extensively studied,
and numerous discoveries in this regard have already been published. Taking that aspect
into account, DisGeNET [17] is a database that can gather knowledge and offer a tool that
can be used to find established relations between genes and diseases.
DisGeNET incorporates data from expert-curated sources, GWAS catalogues, an-
imal models and the literature. DisGeNET data are consistently annotated with controlled
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terms and community-driven ontologies. It also integrates the literature directly using text-
mining approaches like The Literature Human Gene Derived Network (LHGDN) [18] and
BeFree data, obtained using the BeFree System, which obtains gene-disease associations
from MEDLINE abstracts [19] [20].
This database provides several ways to gather its findings, whether it be through
the main web portal, a web API, a SQL database or an all in one file. The results obtained
are a score that associates a gene to a disease.
There are other databases that are publicly available , like DISEASES [21], Poly-
Search2 [22], and DigSee [23]. However, DisGeNET contains more resources than any other
database, and has a higher number of citations in the latest publications. In Chapter 4 of
this thesis, we propose a knowledge-base integrated approach that enhances conventional
methods such as those proposed in Chapters 2 and 3, and it can be used with any machine
learning project that deals with cancer data sets.
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1.5 Thesis Organization
This thesis is organized in five chapters. The first chapter is an introduction to the rel-
evant fields and the main terms used in the thesis. Chapter 2 discusses how to utilize
machine learning techniques to identify Gleason Groups based on mRNA transcripts and
gene expressions. This involves a multi-class classification problem that was solved using
a hierarchical model:
Chapter 2: Hamzeh, O., Alkhateeb, A., Zheng, J. Z., Kandalam, S., Leung,
C., Atikukke, G. & Rueda, L. (2019). A Hierarchical Machine Learning Model to Discover
Gleason Grade-Specific Biomarkers in Prostate Cancer. Diagnostics, 9(4), 219.
Chapter 3 covers the implementation of a machine learning approach that uses
feature selection methods and classification models to predict the location of the prostate
tumours based on gene expression:
Chapter 3: Hamzeh, O., Alkhateeb, A., & Rueda, L. (2018, April). Predicting
Tumor Locations in Prostate Cancer Tissue Using Gene Expression. In International
Conference on Bioinformatics and Biomedical Engineering (pp. 343-351). Presented at
the 6th International Work-Conference on Bioinformatics and Biomedical Engineering,
IWBBIO 2018, Granada, Spain, April 25–27, 2018.
In Chapter 4, we propose an integrative feature selection method that utilizes lit-
erature from online databases to integrate knowledge of gene to disease relation to enhance
the feature selection methods:
Chapter 4: Hamzeh, O., & Rueda, L. (2019, September). A Gene-disease-based
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Machine Learning Approach to Identify Prostate Cancer Biomarkers. In Proceedings of
the 10th ACM International Conference on Bioinformatics, Computational Biology and
Health Informatics (pp. 633-638). Presented at the Machine Learning Models for Multi-
omics Data Integration MODI 2019, a workshop held at the 10th ACM Conference on
Bioinformatics, Computational Biology, and Health Informatics (ACM-BCB), in the , Ni-
agara Falls, New York, September 7-10, 2019.
Finally, Chapter 5 concludes the thesis and highlights the contributions and some
of the drawbacks of the implementations covered inside this thesis, and also discusses
possible avenues for extension of the proposed approaches and future work.
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A Hierarchical Machine Learning




Cancer is among the main causes of death worldwide. Among males, prostate cancer is
the cancer type with the highest incidence; 1.276 million new cases were diagnosed in 2019
[1]. To date, most cancer studies have concentrated on finding biomarkers that enable
differentiating malignant tumours from benign ones. More recent studies, though, have
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focused on specific clinical aspects of tumours, such as recurrence, progression, survivability,
and metastasis, among others.
In the 1950s, Denoix devised a system that categorises solid tumours into different
stages [2]. The classification (TNM) of cancer progression is done by utilising (T) the
extension and the size of the main tumour, (N) the lymphatic involvement, and (M) the
metastasis levels [3]. In prostate cancer, these characteristics are also used to assign a
metric of tissue organisation and disease aggressiveness called the Gleason score. That
score is calculated by adding two numbers: the most common pattern of the tumour cells
is used as the first number, while the second number corresponds to the next most common
pattern. Each individual score varies from 3 to 5, depending on the aggressiveness of the
tumour, where the highest score means the most aggressive form of cancer [4]. Epstein
et al., however, indicated that Scores 2–5 are no longer assigned to the tissue and these
multiple scores can be categorized together with score 6 as group 1, yielding categories
as depicted in Table 1.1. They are used to determine prognosis of disease. As such, we
have used it as the main scheme for prostate cancer score categorization in our method to
detect transcriptomic biomarkers that can accurately classify specific Gleason scores and
groups. This categorization strategy has been shown to clearly indicate cancer recurrence,
and improve the prognostic role of the Gleason score [5].
Recent prostate cancer research has greatly focused on identifying gene expres-
sion patterns that correlate with disease progression, and can be used as predictive tools
for patient treatment and outcome. Moreover, advances in next generation sequencing
(NGS) technology have made genomic data analysis widely available. The output of NGS
sequencers requires preprocessing algorithms to do things such as align the reads to a ref-
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erence human genome and assemble them into transcripts. Many genomic tools that align
the RNA-Seq reads to the human genome have been proposed, especially BLAST is one of
the first tools developed to align reads [6]. TopHat2 is a widely used, open-source tool that
incorporates Bowtie sequence alignment to align reads [7]. STAR is the fastest RNA-Seq
sequence alignment algorithm to date, although it requires huge computational resources
to perform efficiently [8]. Based on the need for understanding the biological basis of the
visual Gleason microscopic assessment, Roberto et al. conducted a gene expression pro-
filing on two groups of Gleason scores 6 and 7, or high, using a metabolic gene panel.
The panel consists of many gene members of the JAK/STAT pathway [9]; this pathway
is involved in processes such as immunity, cell division, cell death and tumour formation.
In this study, we analysed the transcription level of different Gleason scores to find genes
that can identify one specific Gleason group from the others.
In addition, machine learning applications in genomic analysis have become a solid
approach to analysing RNA-Seq data for studying a multitude of diseases. Alkhateeb et al.
proposed a supervised method to discover biomarkers that can predict the likelihood that
a prostate cancer tumour will progress to the next stage [10]. Arvaniti et al. proposed a
deep learning approach to predict Gleason scores [11]. Their model was trained using tissue
microarray (TMA) images of 641 patients with varying Gleason scores, and validated using
245 patient samples with Gleason scores that were reviewed by pathologists. Although the
study by Arvaniti et al. reported decent performance measurements (average accuracy
85.72%, and recall 57%), it did not report the panel of biomarker genes that were used by
the trained convolutional neural network (CNN) to predict Gleason scores. Citak-Er et al.
proposed a machine learning approach for predicting Gleason scores [12]. Their method
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uses a support vector machine (SVM) on prostate images to learn the visual attributes of
the disease and to predict the disease outcome. That study was conducted on a limited
cohort of prostate cancer patients, and the results showed a higher sensitivity over the
specificity in the prediction model (accuracy = 76.83%; sensitivity = 83.38%; specificity =
68.36%).
The focus of this study was to identify genes that can be used to differentiate
specific Gleason groups. This work is an extension of our previously proposed predic-
tion model, which was based on analysing the RNA-Seq data from patients with different
Gleason scores [13]. The method can track transcripts associated with specific genes, in
addition to their corresponding expression values. The results of the initial trial show great
potential to build a simple system to diagnose Gleason scores based on NGS data.
2.2 Materials and Methods
The primary data set used in this study was retrieved from the National Center for Biotech-
nology Information (NCBI) and is referenced with Gene Expression Omnibus (GEO) num-
ber GSE54460 [40]. This RNAseq prostatectomy data set was generated from 106 prostate
cancer tissue samples and validated on an independent data set with 140 patients. Several
health sciences centres provided data samples as well. The Moffitt Cancer Center (MCC)
contributed ten samples from patients who underwent radical prostatectomies between the
years 1987 and 2003. The Sunnybrook Health Sciences Centre at the University of Toronto
provided 35 samples from patients treated for prostate cancer between the years 1998 and
2006. The Atlanta Veterans Administration Medical Center (AVAMC) donated 61 tissue
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Table 2.1: Numbers of samples in different Gleason groups.
Gleason Score Number of Samples
6 10
3 + 4 = 7 55
4 + 3 = 7 24
8 10
9 4
samples from patients who underwent radical prostatectomy between the years 1990 and
2000. Table 2.1 shows the number of samples grouped by their Gleason group. Based on
Epstein’s model, there are five Gleason groups: 4 + 3 = 7, 3 + 4 = 7, 6, 8, and above 8 (9
and 10).
This data set was generated by using the Illumina HiSeq 2000 NGS on paired-end
sequences of length 51 bp each. The pre-processing pipeline starts by obtaining the RNA-
Seq samples and pre-processing them using SRAtools [41], as depicted in Figure 1.3. The
process continues by incorporating the STAR aligner [8] to align the samples reads into
the human genome (hg19). Then, the process assembles the transcripts and quantifies the
reads into the assembled transcripts using RSEM [42]. RSEM uses transcripts per million
of reads (TPM) to compute the quantification of each read into a transcript.
NGS technology allows us to read the patient’s genome and generate a significant
amount of raw data in a snapshot. However, the underlying process yields artefacts, and
pre-processing must be done before the downstream analysis. These artefacts include
duplication and bias reads [43], among others. Counting the reads that are assembled by
mapping them to the human genome gives accurate indicators of transcript expression.
Since the samples are pair-ended reads, TPM is used to measure the read quantification
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rather than reads per kilobase per million of reads (RPKM) [44]. Additionally, the reason
for choosing TPM instead of fragments per kilobase per million (FPKM) [45] is that TPM
normalises the reads to the length of the gene first, which makes it easier to compare the
quantified reads among different samples.
2.2.1 Class Imbalance
Some classes have a markedly lower number of samples than the others, which may cause
some classifiers to become biased towards the majority class. To solve this problem, mul-
tiple resampling methods were deployed and tested to identify the specific method that
would yield the best solution for a particular data set. After applying multiple oversam-
pling and under-sampling methods, the best option was found to be the synthetic minority
oversampling technique (SMOTE) [46] for oversampling the minority class, while the neigh-
bourhood cleaning rule (NCL) [47] was used for undersampling the majority class.
NCL works by removing any sample whose class is different from the class of at
least two of its three nearest neighbours. SMOTE, instead, introduces a new way of creating
new samples, by utilising the feature vector that connects each sample and introduces a
new synthetic sample along the line that connects the two underlying samples. The exact
location of the new sample on the line itself is calculated by measuring the Euclidean
distance between the two samples and multiplying that value by a random number between
0 and 1. Figure 2.1 shows a hypothetical example of the mechanism followed by SMOTE,
by adding new synthetic samples randomly along the line that connects each of two original
samples in a minority class. The blue points represent the original samples, while the amber
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Figure 2.1: Hypothetical example that shows how the synthetic minority oversampling
technique (SMOTE) works.
points represent the synthetically generated samples.
2.2.2 Feature Selection
As the output of the pre-processing step, the method retrieved 41,971 transcripts along with
their corresponding quantifications measured by TPM. Such a large number of transcripts
leads to a complex classification model, mostly due to the curse of dimensionality [48].
Thus, feature selection was applied to reduce the dimensionality of the problem. The first
step of the feature selection is to filter the transcripts based on their information gain values
by selecting the ones with the highest scores. The filter method, which is called attribute
evaluator, is the procedure by which each attribute (transcript) in the data set is assessed
22
with regard to the class. This procedure produces a list of attributes (transcripts) with a
score for each attribute showing its effect on the actual class. Then, the attributes with the
highest scores are selected, discarding those with lower scores. In this work, information
gain (IG) was used as an attribute evaluator to rank each attribute vector [49]. The IG of
attribute vector X concerning class vector A is defined as follows:
IG(A,X) = H(A)−H(A|X), (2.1)
Where, H(A) is the entropy of the class vector A and H(A|X) is the conditional
entropy of A given X.
After filtering the transcripts based on their IG scores, a wrapper-based feature
selection algorithm that uses minimum redundancy maximum relevance (mRMR) is used to
narrow down the most relevant, least redundant transcripts to a few per group; mRMR has
the capability of incorporating any classifier to select features (transcripts) that minimise
the redundancy while increasing the correlation to the class vector [50]. The wrapper
method adds up the features that minimise redundancy (W ), and maximize the relevance














I(h, i) , (2.3)
where S is the set of features, I(i, j) is the mutual information between features (i, j), and
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h is the class, in our case, the five Gleason groups.
2.2.3 Classification
The problem dealt with is multi-class classification, which was solved using the one-versus-
rest approach. There are five different classes, which correspond to the five distinct Gleason
groups. To apply a one-versus-rest approach, we created five different data sets from
the actual data. For each data set, we set one of the classes to form the positive class,
while the rest of the classes were combined to form the negative class. The classification
pipeline resembles a binary tree structure, where each internal node is a binary classification
problem (see Figure 2.4). Starting from the root, in the one-versus-rest classification, we
remove the samples that belong to the chosen class earlier. We repeat the same steps of
building data sets for the remaining four different classes. At each node, the best class
is chosen and the classification continues in the same fashion until two classes are left.
To select the best class at each node, different performance measures can be used; The
accuracy, sensitivity, and specificity are used in this study. Note that the hierarchical
model involves list processing, and as such, any error at a particular node is propagated
down the tree structure. In a greedy-like algorithm, we minimise the error propagation by
choosing the class with the highest accuracy at each internal node.
2.2.4 Identifying Transcripts within Different Gleason Scores
We used the Scitkit-learn [51] library to apply different classification algorithms to the
final transcripts selected. This step identifies which transcripts can decide a Gleason group
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from the others based on their quantification values. Standard classifiers such as Näıve
Bayes and SVM were used in this study to build the classification model. Naive Bayes is
a probability-based classifier that applies the well-known Bayes’ theorem, while assuming
that the features are independent of each other [52]. While being simple, Näıve Bayes
has been shown to perform very well in many problems and avoid overfitting. An SVM
classifier was also used to build a prediction model using the transcripts selected in the
previous step [53]. The advantage of SVM is its exceptional generalisation power, especially
in high-dimensional data with a small number of samples. Figure 2.2 shows the pipeline
followed in this study.
2.3 Results
The first data set used in this study is a collection of 104 samples and their TPM values.
Stated as a classification problem, this study designates five classes obtained from joint
Gleason groups. The distribution of each group is shown in Figure 2.3. The data set
was mapped against the human genome version hg19 with 88% to 99% uniquely aligned
reads. Throughout a 10-fold cross-validation model, we obtained a total of seven samples
that were misclassified and another 97 samples that were classified correctly, with the total
number of samples being 104. The accuracy of the model was calculated from the total
number of correctly classified samples divided by the total number of samples.
The model also identified six gene transcripts that are differentially expressed
in the five different Gleason scores. Of these, the corresponding genes shown in Tables
2.2–2.5 are the most relevant for identifying prostate cancer; the Gleason scores using the
25
Figure 2.2: Machine learning pipeline used in the proposed method.
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Figure 2.3: Gleason groups and their distributions.
hierarchical method are illustrated in Figure 2.4. Different classification methods for each
stage within the hierarchy are shown in Table 2.6.
The first node of the hierarchy yields 94% accuracy in identifying Gleason score
3 + 4 = 7 compared to the other scores. The samples are then passed through node 2,
in which Gleason score 4 + 3 = 7 was identified from the rest with a prediction accuracy
of 98%. The other samples were then passed through node 3, where Gleason score 6 was
identified with the accuracy of 100%. The remaining samples were finally processed in
the last node, where the Gleason score 8 was identified from the Gleason score 9 with the
accuracy of 100%. Due to the similarity in the aggressiveness of the tumour and the low
number of samples, all the other Gleason scores were merged in the last node.
Figure 2.5 shows the classifiers that have been utilised to identify the set of tran-
scripts that differentiate specific Gleason groups against the rest. The classifiers are rep-
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Figure 2.4: Hierarchical tree of classifications of Gleason groups against the rest, along
with the corresponding classification accuracies.
Table 2.2: Set of resulting transcripts in Gleason group 1.
Transcript Gene Description
NM 003350 UBE2V2 ubiquitin conjugating enzyme E2 V2
(UBE2V2 )
NM 153051 MTMR3 myotubularin related protein 3 (MTMR3 ),
transcript variant 2
NM 207445 C15orf54 chromosome 15 open reading frame 54
(C15orf54 ),
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Table 2.3: Set of resulting transcripts in Gleason group 2.
Transcript Gene Description
NM 001170880 GPR137 G protein-coupled receptor 137 (GPR137 ),
transcript variant 2
NM 001198827 C8orf58 chromosome 8 open reading frame 58
(C8orf58 ), transcript variant 3
NM 004629 9p13.3 Fanconi anemia complementation group G
(FANCG)
NM 001098268 LIG4S DNA ligase 4 (LIG4 ), transcript variant 3
NM 016641 GDE1 glycerophosphodiester phosphodiesterase 1
(GDE1 ), transcript variant 1
NM 002445 MSR1 macrophage scavenger receptor 1 (MSR1 ),
transcript variant SR-AII
NM 001126337 TUFT1 tuftelin 1 (TUFT1 ), transcript variant 2
NM 033071 SYNE1 spectrin repeat containing nuclear envelope pro-
tein 1(SYNE1 ), transcript variant 2
NM 052906 ELFN2 extracellular leucine rich repeat and fibronectin
typeIII domain containing 2 (ELFN2 ), tran-
script variant 1
NM 000714 TSPO translocator protein (TSPO), transcript variant
PBR
NM 004374 COX6C cytochrome c oxidase subunit 6C (COX6C )
NM 001007544 C1orf186 chromosome 1 open reading frame 186
(C1orf186 )
NM 001276438 KCNJ15 potassium voltage-gated channel subfamily J
member 15 (KCNJ15 ), transcript variant 7
NM 001252021 TOR2A torsin family 2 member A (TOR2A), transcript
variant 7
NM 152612 CCDC116 coiled-coil domain containing 116 (CCDC116 ),
transcript variant 1
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Table 2.4: Set of resulting transcripts in Gleason group 3.
Transcript Gene Description
NM 001136224 RCOR3 REST corepressor 3 (RCOR3 ), transcript vari-
ant 2
NM 001017967 MARVELD3 MARVEL domain containing 3 (MARVELD3 ),
transcript variant 1
NM 006099 PIAS3 protein inhibitor of activated STAT 3 (PIAS3 )
NM 152395 NUDT16 nudix hydrolase 16 (NUDT16 ), transcript vari-
ant 2
NM 006473 TAF6L TATA-box binding protein associated factor 6
like (TAF6L)
NM 001145541 TCP11L1 t-complex 11 like 1 (TCP11L1 ), transcript vari-
ant 2
NM 182501 MTERF4 mitochondrial transcription termination factor
4 (MTERF4 )
Table 2.5: Set of resulting transcripts in Gleason group 4.
Transcript Gene Description
NM 001258330 EPB41L1 erythrocyte membrane protein band 4.1 like 1
(EPB41L1 ), transcript variant 4
Table 2.6: Classification performance for each step in the hierarchy.
Gleason Group Accuracy Sensitivity Specificity F-Measure MCC ROC
3 + 4 = 7 vs. Res 94 95 94 0.94 0.88 95
4 + 3 = 7 vs. Rest 98 100 96 0.98 0.96 99
6 vs. Rest 100 100 100 1.00 1.00 100
8 vs. 9 100 100 100 1.00 1.00 100
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Figure 2.5: Accuracy obtained by each classifier for classifying one versus the rest for all
five Gleason groups.
resented on the x-axis, while the classification performance measurements are represented
on the y-axis.
Näıve Bayes outperformed the other classifiers, as it distinguished the first Glea-
son score node from the rest with the accuracy of 94%, the second node with a higher
accuracy of 98%, and the last two Gleason score nodes with the accuracy of 100% accu-
racy, as shown in Figure 2.5.
2.4 Discussion
Many of the genes that encode the differentially expressed transcripts identified in this
study have been previously shown to play various roles in cancer. Some have been shown
to promote cancer progression, while other play a protective role. For example, UBE2V2,
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Figure 2.6: Classification accuracies obtained after applying the model on the second data
set.
whose gene’s transcript was selected in the third node of our hierarchical model, has been
shown to protect cells by mediating DNA repair functions [16]. In familial prostate cancer,
however, a high frequency variant of UBE2V2 was identified and found to affect DNA
repair and androgen signaling [17]. In our model study, a different quantification of the
UBE2V2 transcript was able to predict Gleason score 6 (group 1) in the first data set.
Differential expression of UBE2V2 has also been associated with poor prognosis in breast
cancer [18].
Our study also reveals that the differential expression of GPR137 expression and
EPB41L1 is associated with tumours of Gleason scores 3 + 4 = 7 and 8, respectively.
Earlier studies show that proteins encoded by EPB41L1 are associated with the proper
organisation of the cell cytoskeleton, and that EPB41L1 plays an important role in the
negative regulation of cell metastasis, migration, and invasion. Expression of EPB41L1
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has been observed to be lower in prostate cancer compared to normal cells. Although it
remains unclear, disruption of normal EPB41L1 expression may play an important role in
disorganised cell and tissue structures associated with higher grade prostate cancer [19],
and thus link its deregulation to prostate cancer progression and prognosis. Furthermore,
reduced expression of EPB41L1 plays an important role in recurrence and has been asso-
ciated with highly metastatic lung and breast cancer [20]. EPB41L1 was also shown to be
differentially expressed in gastric cancer [21]. On the other hand, GPR137 expression has
been shown to be upregulated in prostate cancer tissues compared with paracancerous tis-
sues. Moreover, knockdown of GPR137 resulted in decreased cell proliferation and colony
formation in PC-3 and DU145 prostate cancer cell lines, and was associated with cell cycle
arrest at G0/G1 phase. GPR137 suppression also decreases the migration and invasive
abilities of PC-3 cells, suggesting that GPR137 plays a role in prostate cancer progression
and metastasis [22].
Differential expression of PIAS3 and Rest Corepressor 3 (Rcor3) were both as-
sociated with tumours of Gleason score 4 + 3 = 7. While very little is known about the
role of Rest Corepressor 3 (Rcor3) in prostate cancer, it has been shown to act as an
antagonist of cell differentiation [23], a characteristic of prostate tumours with Gleason
score 4 + 3 = 7 [4]. On the other hand, differential PIAS3 expression has been observed
in a variety of human cancers, including lung, breast, prostate, colorectal, and brain [24].
PIAS3 is expressed in prostate cancer cells, and its expression is induced in response to
androgens [26, 25]. Although PIAS has been shown to enhance the transcriptional activ-
ity of androgen receptors (AR) in prostate cancer cells, other studies have revealed that
ectopic overexpression of PIAS3 suppresses AR-mediated gene activation induced by di-
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hydrotestosterone (DHT) [24]. PIAS3 acts as a negative regulator of AR transcriptional
activity and signaling through direct protein–protein interaction. Recent findings have
also revealed that AR is also differentially correlated with Gleason score patterns in both
primary and metastatic prostate cancer, where it is upregulated in Gleason group 4 and
downregulated in Gleason pattern 5.
PIAS3 is a member of the mammalian PIAS family consisting of four mem-
bers: PIAS1, PIAS2, PIAS3, and PIAS4 [27]. PIAS3 protein directly binds to several
transcription factors and either blocks or enhances their activity. PIAS3 is also specific
inhibitor of signal transducer and activator of transcription 3 (STAT3), a transcription
factor and member of the Janus kinase (JAK)/STAT signaling pathway [28, 29]. This
signaling pathway has been a target of interest in many cancer studies in recent years.
In prostate cancer, the expression levels of JAK/STAT have been shown to impact the
progression of the disease [30, 31]. As an inhibitor of STAT3, PIAS3 blocks the trans-
activation and binding of STAT3 to specific DNA elements via protein–protein interac-
tions, thereby inhibiting STAT3-mediated gene activation. Figure 2.7 depicts the protein–
protein interaction among genes with 4 + 3 = 7 and 6 scores, as extracted from Pro-
teomicsDB (https://www.proteomicsdb.org/proteomicsdb/#human/proteinDetails/
86810/interactions) based on experimental and epidemiological evidence. The Figure
shows that both PIAS3 and UBE2V2 share the same protein interaction network.
PIAS3 is also the only member of the PIAS family that has been shown to di-
rectly interact with Stat5a/b and repress Stat5-mediated transcription [32]. Stat5a/b is
constantly active in human prostate cancer [33], associated with high histological grades
[34], and a predictor of early prostate cancer recurrence [35]. Transcription factor Stat5a/b
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Figure 2.7: An interactive figure taken from proteomics database STRING. It shows
neighbouring protein binding and pathway interactions for a given gene using STRING
and KEGG pathway analysis. Here, the gene of interest is PIAS3, an identified possible
biomarker in the 4 + 3 = 7 score. The figure shows the interaction between other proteins
and pathways associated with it.
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has been shown to regulate the viability and growth of human prostate cancer cells [36, 37].
Moreover, in vitro inhibition of Stat5a/b induces apoptosis in human prostate cancer cells
[33, 38]. In vivo, Stat5a/b inhibition blocks prostate cancer subcutaneous and orthotopic
xenograft tumour growth in nude mice [38]. Although studies have revealed an inhibitory
role for PIAS3 against Stat5a/b-driven gene transcription and disease progression in breast
cancer, the predominant Stat5a/b protein that binds to DNA has been shown to be N-
terminally truncated in human prostate cancer cells and clinical prostate cancers [39]. Fur-
ther studies have demonstrated that the N-domain of Stat5a/b binds to PIAS3. Hence, the
truncated form of Stat5 in prostate cancer cells evades PIAS3 -mediated transcriptional in-
hibition, thereby increasing prostate cancer growth and progression. Thus, the proteolytic
cleavage of the N-terminus of Stat5a/b may be a mechanism by which Stat5 evades the
transcriptional repression by PIAS3 in prostate cancer cells. This further indicates the
complexity of intracellular protein interactions and its role in disease progression.
Our study applied a novel machine learning model to identify differentially ex-
pressed, prostate cancer stage-specific transcripts. Although the application of this model
to other related data sets is required to further valid our findings, the use of this model
in conjunction with in vitro and in vivo biological studies will aid in elucidating the intri-
cate molecular relationships between the identified transcripts. Moreover, this will provide
more insight into predicted prognostic outcomes and the development of effective thera-
peutic strategies against prostate cancer progression.
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2.5 Conclusions and Future Directions
Identifying novel biomarkers that are clinically associated with specific Gleason groups
in prostate cancer is vital for the diagnosis and treatment of the disease. Utilising NGS
data and machine learning techniques, a supervised learning method was proposed to find
group-specific sets of transcripts with significant different levels of quantification values.
The transcripts, along with the corresponding genes, identified by the proposed machine
learning method, were found in the literature to play crucial roles in cancer pathogenesis;
key transcripts were strongly correlated to prostate cancer. To validate the model, we also
tested it on a gene expression data set, showing that the resulting genes are related to
prostate cancer progression.
37
The work presented in this chapter opens the way for future directions of
research. One of these is to apply and adjust the same method to other cancer types.
Another possible avenue would be to consider analysing samples from patients who have
progressed through more than one Gleason group. This method aims to eliminate
confounding factors between patients, potentially leading to a clearer analysis of
differential gene expression between different grades of prostate cancer. In addition, a
multi-omics model based on different types of genomics data for this problem could be
investigated, which may provide a comprehensive analysis of the progression, diagnosis,
and treatment of the disease. References
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Chapter 3
Prediction of Tumor Location in
Prostate Cancer Tissue Using a
Machine Learning System on Gene
Expression Data
3.1 Introduction
Cancer is among the leading causes of death worldwide. In 2013, there were 8.2 million
deaths, and 14.9 million cases of cancer incidence [1]. As with all cancer diseases, in-
vestigating prostate cancer at the molecular level reveals transcriptional and regulatory
mechanisms of the tumour biology. Traditionally, prostate cancer studies centered pri-
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marily on finding biomarkers for differentiation between benign and cancerous tumors.
Recently, studies have considered some other aspects of the tumours including progression,
metastasis, location, and recurrence, among others.
Traditional methods for detecting prostate cancer such as prostate specific antigen
(PSA) blood test, transrectal ultrasound image (TRUS) guided biopsy, and digital rectal
exam (DRE) do not measure up to the medical standards. PSA blood test statistical results
shows a specificity of 61% and a low sensitivity of 34.9%, while TRUS-guided biopsy and
DRE are invasive [2].
In addition, multiparametric magnetic resonance imaging (MRI) of the prostate
is a functional form of imaging used to augment standard T1- and T2-weighted imaging.
Multiparametric MRI may miss up to 12% of cancer cases [3]. In addition to the need
for reducing the number of biopsies come most of the time with pain, fever, bleeding,
infection, transient urinary difficulties, or other complications that require hospitalization
[4]. Finding gene biomarkers of prostate cancer location and analyzing their proteomics can
help clinically understand the development of the disease and improve treatment efficiency.
Machine learning approaches, on the other hand, have been successfully applied
on prostate cancer data to identify gene biomarkers of the disease [5, 6]. Using next gen-
eration sequencing and the power of machine learning, Singireddy et al. devised a support
vector machine (SVM) classifier to identify biomarker genes associated with prostate can-
cer progression. The biomarkers were able to discriminate consecutive prostate cancer
stages with high performance [5]. Earlier, Hamzeh et al. proposed a method for finding
groups of transcripts that are differentially expressed among the different Gleason stages
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[7]. The identified transcripts can be used to predict the actual Gleason score for new
samples, and these transcripts belong to genes that are well known to play important roles
in prostate and other types of cancer. Yu et al. demonstrated that their method is efficient
for predicting prostate cancer aggressiveness based on gene expression patterns [8].
Similarly, machine learning approaches have been used for cancer localization
prediction [10, 9]. Artan et al. proposed a prediction model based on a cost-sensitive SVM.
The model is used to analyze a large data set of multispectral magnatic resonance imaging
(MRI). This method improves the cost-sensitive SVM using a segmentation method by
combining conditional random fields (CRF) with a cost-sensitive framework. Incorporating
spatial information leads to better localization accuracy [9]. As stated earlier, prediction by
imaging is still inaccurate, not specific and hence needs more improvement. In an attempt
to find different gene expression levels between two lists, the first contains the expression
levels of colon tumor cells, while the latter for rectal tumor cells, Sanz-Pamplona et al.
applied agglomerative hierarchical clustering to display the classification ability between
both lists. Both lists have very similar gene expression levels except for several HOX genes
which are found to be associated with tumor location [10].
In this work, we are extending our previous method for classifying different lat-
erality prostate samples which are left unary, right unary, or bilateral [11]. The results of
this multi-class model are set of genes that can determine a specific class from the others.
The literature shows that these genes are related to prostate cancer, which may lead to be
a potential biomarkers for prostate cancer laterality.
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3.2 Materials and Methods
RNA-sequencing data from The Cancer Genome Atlas (TCGA) Prostate Adenocarcinoma
(PRAD) was used. This data set consists of 450 samples for different patients with different
cancer locations. There are three primary locations that the tumor might be located within
the prostate: left, right and bilateral. Figure 3.1 shows the actual possible locations, while
Table 3.1 describes the number of samples in each location.
Figure 3.1: Possible locations of the tumor in prostate cancer.
Table 3.1: Number of samples in each prostate cancer tumor location.
Left Bilateral Right
18 431 38
Gene expression data was downloaded through the cBioPortal for cancer genomics
database [12]. Each sample contains expression levels for each of the 60,488 genes; the gene
expressions are given in terms of Transcripts Per Kilobase Million (TPM) values. The aim
of this study is to identify genes which are associated with specific tumor locations, and
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hence we need to use the genes as features and the actual locations as classes to build a
model to predict locations for future samples. Since most of the samples are bilateral, we
deal with a class imbalance problem. We used the resampling method proposed in [13] as
measure to lower the effect of this imbalance.
3.2.1 Resampling
By observing Table 3.1, we clearly notice that there is a class imbalance problem, where
the number of samples in the right class (38) is almost twice as large as that of the left
class (18). while the number of samples of the bilateral class (431) is more than twenty
times larger than the left class and more than ten times larger than the right class.
Figure 3.2: Synthetic Minority Oversampling Technique (SMOTE) works by adding new
synthetic sample randomly along the line that connects each of the two original samples.
To solve this problem, multiple resampling methods were deployed and tested
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to identify a method that would yield the best solution for our data set. Oversampling
provides a fast solution for classes left and right. This method duplicates samples from
the minority classes and adds them until yielding a similar number of samples for each
class. Applying oversampling directly did resolve the class imbalance problem and provided
high accuracy for classifiers, although after taking a closer look at the samples used in
these classifiers, we noticed that there was a major overfitting. Based on the literature
[24, 25], we selected the combination of oversampling Synthetic Minority Oversampling
Technique (SMOTE) [26] and Neighborhood Cleaning Rule (NCL)[27] for under-sampling
the majority class. Junsomboon et al. reported that the combination (NCL+SMOTE)
outperfomed another set of methods for handling the imbalance data sets. They have
applied this combination on different health related data sets [24]. NCL uses the Wilson’s
Edited Nearest Neighbor Rule (ENN) to remove majority class outliers [28]. Batista et al.
reported a high performance for SMOTE+ENN in handling imbalance data set [25].
NCL works by removing any sample whose class is different from the class of
at least two of its three nearest neighbors. SMOTE introduces a new way of creating
new samples, by utilizing the feature vector connecting each sample and introducing a
new synthetic sample along the line that connects the two underlying samples. The exact
location of the new sample on the line itself is calculated by measuring the distance between
the two samples and multiplying that value by a random number between 0 and 1. Figure
3.2 shows the behavior of SMOTE.
Applying these two methods allowed us to use three classes that are balanced.
Table 3.2 shows the number of samples after applying the SMOTE+ENN resampling meth-
ods.
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Table 3.2: Number of samples in each prostate cancer tumor location after applying the
SMOTE+ENN resampling methods.
70 vs 70 240 vs 240 40 vs 40
Left vs rest Bilateral vs rest Right vs rest
3.2.2 Feature Selection
Dealing with a huge number of features lead us to the problem of curse of dimensionality.
As such, we use machine learning techniques to lower the number of features used for
classification. We applied the information gain (IG) feature selection method to rank all
the genes with a score that relates to the highest information gain against the different
classes. We then chose the attributes with the highest scores, discarding those with lower
scores. In this chapter, the IG attribute evaluator [14] is used to evaluate each attribute.
IG of feature X with respect to class Y is calculated as follows:
IG(Y,X) = H(Y )−H(Y |X) (3.1)
Here, H(Y ) is the entropy of class Y and H(Y |X) is the conditional entropy of
Y given X.
The next step is to choose the best set of attributes (genes) that provide good
classification among the different classes.
A wrapper that binds feature selection and classification methods is used. The
feature selection method is the minimum redundancy maximum relevance (mRMR), which
takes features that contain minimum redundancy while at the same time have high corre-
lation to the classification variable [15]. The equation for minimizing redundancy (W ) and
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maximizing the relevancy (V ) is the following:











where S is the set of features, I(i, j) is mutual information between features (i, j), h is the
class.
3.2.3 Classification
We deal with a multi-class classification problem which is solved by using the one-versus-all
approach. We have three different classes which are the three different locations. To apply
the one-versus-all approach, we need to create three separate copies from the actual data
set. For each data set, we set one of the classes to positive, and the rest of the classes are
combined together to form the negative class. We used accuracy, sensitivity and specificity
to choose the best classification method.
Multiple classification methods were applied on the data to identify which meth-
ods separate the locations better. Accordingly, the probabilistic classifier Naive Bayes that
applies Bayes’ theorem with the assumption of independence between the features [16] was
tested. SVM was also used to build a classification model based on the features selected
in the previous step [17]. The other classifier that was tested is random forest [18], which
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attempts to build multiple decision tree models with different samples and different initial
variables.
The Weka open source libraries were used to run different classification algorithms
on the minimized number of features to identify which genes are differentially expressed in
the different locations [19].
3.3 Results and Discussion
The different classifiers produced varied results as observed in Table 3.3 and Figure 3.3.
The classifiers were chosen based on accuracy and precision, as leading high accuracy
with low precision is not a good criterion at all. The accuracy measures the number of
correctly classified samples divided by the number of all samples, while the precision is the
true positive rate which measures the number of true positive calls divided by all positive
calls. Table 3.3 shows the actual accuracy and precision for each classifier. The highest
accuracy and precision for the different classifiers came from the SVM Radial basis function
kernel (SVM-RBF) classifier. Grid search optimization was applied to fine tune the RBF
classifier, it was able to separate the different locations by an accuracy of 99%. Random
forest managed to result in high accuracy too, while the naive Bayes classifier results were
not satisfactory.
Table 3.4 show the actual genes that were identified by SVM-RBF. These genes
can be used to predict the location of the prostate cancer tumor very accurately from gene
expression data.
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Figure 3.3: Different classifiers accuracy for the different locations.
Table 3.3: Accuracy and precision for classifying each class versus the rest.
Classifier Accuracy Precision Accuracy Precision Accuracy Precision
SVM RBF 99 97 99 97 99 97
Naive Bayes 88 78 82 78 80 78
Random Forest 93 85 90 85 95 85
Left vs rest Bilateral vs rest Right vs rest







Left vs rest Bilateral vs rest Right vs rest
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Throughout our model 10-fold cross-validation was used. The proposed method
identified 12 genes that are differentially expressed among the three different possible lo-
cations.
It is important to highlight that most of the genes identified in this work have been
previously characterized and described to play some role in prostate cancer as well as other
types of cancer. SNAI2 is a gene shown [20] to be silenced in prostate cancer and regulates
neuroendocrine differentiation, metastasis-suppressor, and pluripotency gene expression.
Likewise, the results shown in [21, 22] indicate that increased TAF1/7 expression
is associated with progression of human prostate cancers to the lethal castration-resistant
state. In a similar way, the results reported in [23] found that tumor cell expression of
HLA-DMB is associated with increased numbers of tumor-infiltrating CD8 T lymphocytes
and both are associated with improved survival in advanced serous ovarian cancer.
Figures 3.4-3.6 depict the ROC curves for all the classes versus the rest at each
node. The area under the curve AUC for SVM-RBF tends to be further towards the
north west with 0.99 value in the three figures, which means the best overall performance
across all classes versus the rest. All other classifiers were inconsistent in the three figures.
However, random forest performed very well in later false positive rates for both left and
right classes with overall performance 0.87, 0.84 in order for both classes. it slightly
outperformed the SVM-RBF in one point at both classes. but as we stated earlier, it was
inconsistent through out different running parameters for false positive rates.
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Left versus Rest - ROC
SVM RBF ROC area = 0.99)
Random Forest ROC area = 0.87)
Naïve Bayes ROC area = 0.56)
Figure 3.4: The ROC curve for left versus the rest using different classifiers.
3.3.1 Biological insight
We have conducted a thoroughly literature review on the most up to date classification,
as well as in the relevant databases and gathered valuable information about the most
relevant genes that we have found in our study. A summary for each gene is given below
and opens the avenue for further studies as well as additional lab experiments that can
corroborate our studies and lead to novel ways of diagnosis, treatment and prognosis of
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Bilateral versus Rest - ROC
SVM RBF ROC area = 0.99)
Random Forest ROC area = 0.79)
Naïve Bayes ROC area = 0.66)
Figure 3.5: The ROC curve for bilateral versus the rest using different classifiers.
the disease.
FBXO21 (F-box protein 21) is part of the multiprotein complex, SCF E3-ligase,
which functions in phosphorylation-dependent ubiquitination. FBXO21 may affect prostate
cancer through different mechanisms, and here we hypothesize two possibilities. Firstly,
ABCB1 is a known tumour drug resistance biomarker because it is a multi-drug efflux
pump linked with the development of metastases [29]. FBXO21 tags ABCB1 for proteaso-
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Right versus Rest - ROC
SVM RBF ROC area = 0.99)
Random Forest ROC area = 0.84)
Naïve Bayes ROC area = 0.57)
Figure 3.6: The ROC curve for right versus the rest using different classifiers.
mal degradation, whereas inhibition of FBXO21 leads to higher expression level of ABCB1.
Secondly, FBXO21 recognizes EID1 in cycling and G0 stage cells and targets it for degrada-
tion. EID1 interacts with retinoblastoma tumour suppressor (pRB), melanoma-associated
antigen (MAGE), and E1A binding protein p300 (EP300) as well as being involved in
the coupling cell cycle exit to cellular differentiation. All available evidence suggests that
FBXO21 may be downregulated in prostate cancer, although further research is desirable
[30].
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RTN1 (reticulon 1) is associated with the endoplasmic reticulum (ER) and is in-
volved in neuroendocrine secretions and membrane trafficking. RTN1 has been known
exert a cancer-specific proapoptotic function. Specifically, RTN1-C regulates the two
mutually exclusive ER stress-induced apoptosis and DNA damage-induced cell death.
Overexpression of RTN1-C results in ER stress-induced cell death mediated by aber-
rantly increased cytosolic Ca2+ due to depletion of ER calcium stores [31]. A recent
publicaiton on prostate cancer shows that silencing RTN1 by siRNA enabled androgen-
independent proliferation of androgen-dependent prostate cancer tumours. The knock-
down of RTN1 increases the nuclear concentration of HDAC8, a multifunctional histone
deacetylase that regulates activity of transcription factors such as nuclear hormone recep-
tors [32]. In particular, it is known that ceramide inhibits androgen receptor activity and
inhibits androgen-independent growth by activation of protein phosphatase 2A (PP2A)
[33]. However, HDAC8-induced depletion of SPTSSA in the ER compromises the ER-
localized ceramide biosynthesis pathway, leading to downregulation of ceramide, partial
inhibition of PP2A and androgen receptor activation in androgen-deprived conditions [32].
Consequently, RTN1 may be a proto-oncogene associated with aggressive, malignant and
androgen-independent prostate cancer.
NDUFA5 (NADH:ubiquinone oxidoreductase subunit A5) is localized to the inner
mitochondrial membrane and functions in the NADH two-electron reduction of ubiquinone
[34]. Complex I, also known as NADH-ubiquinone oxidoreductase, is the first complex
of the mitochondrial oxidative phosphorylation (OXPHOS) system. The energy released
is coupled with generation of the electrochemical gradient necessary for ATP synthesis
[35]. As expected, NDUFA5 activity is lower in hypoxic cells [36]. The Warburg effect
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states that tumour cells demonstrate drastically increased glycolysis activity compared
to oxidative phosphorylation due to target genes upregulated by hypoxia-inducible factor
(HIF) [37]. On the other hand, NDUFA5 is upregulated in HPV+ cervical cancer and its
overexpression may play a role in carcinogenesis through acquiring growth advantage and
resistance against an apoptotic signal [34]. In a recent publication, NDUFA5 also gained
copy numbers in both low-grade and high-grade gliomas. Therefore, NDUFA5 may also
be upregulated in prostate cancer, although further research is necessary to confirm this
hypothesis [38].
POP7 (POP7 homolog, ribonuclease P/MRP subunit) is discovered in S. cere-
visiae. POP7 heterodimerizes to POP6 and binds to the P3 domain of catalytic ribonu-
cleoproteins RNase MRP (mitochondrial RNA processing) and Rpr1 RNA [39]. RNase
MRP is critically important to the viability of eukaryotic cells because it is localized in the
nucleolus and is involved in processing mitochondrial RNAs and regulating mitochondrial
DNA replication [40]. POP1/POP6/POP7 complex is required for telomere elongation
protein (Est1) to associate with the RNP, which is critical during the process of mitosis
for the cell lifespan before its senescence [41]. Despite the critical importance of POP7,
no known human diseases are associated with this gene currently. Further research will be
important to explore the biological significance of POP7.
HLA-DMB (major histocompatibility complex class II, DM beta) is a subunit
of the HLA class II heterodimer found embedded in intracellular vesicles. In antigen-
presenting cells (APC), HLA-DMB is critical in the antigen-presentation machinery by
releasing class II-associated invariant chain peptide (CLIP) from MHC class II molecules
so that the peptide binding site is free to interact with antigenic peptides [42]. A recent
62
publication on prostate cancer research found that HLA-DMB is coexpressed with ERG
and silencing ERG led to significant underexpression of HLA-DMB. Thus, HLA-DMB is
an upregulated tumour-associated gene in prostate cancer [43].
SRSF6 (Serine and Arginine rich Splicing Factor 6) modulates a splicing factor
protein called SFRS12 to determine alternative splicing of mRNA. In a recent publication
on colorectal cancer, SRSF6 targeted ZO-1 (tight junction protein 1) exon23 for alternative
splicing, consequentially disrupting ZO-1 from regulating tight junctions between adjacent
cells [44]. Furthermore, SRSF6 is the direct target of LINC01133, a key SRSF6 modulates a
splicing factor protein called SFRS12 to determine alternative splicing of mRNA. In a 2017
paper on colorectal cancer, SRSF6 targeted ZO-1 (tight junction protein 1) exon23 for al-
ternative splicing, consequentially disrupting ZO-1 from regulating tight junctions between
adjacent cells. In addition, SRSF6 is the direct target of LINC01133, a key downstream
protein of TGF-β signaling pathway which is critical for cell growth and differentiation [45].
Silencing SRSF6 in colorectal cancer tissues inhibited epithelial-mesenchymal transition,
tissue invasion, and metastasis. A study on wound healing found that overexpression of
SRSF6 induces skin hyperplasia due to SRSF6 upregulating Tenascin C and suppressing
the normal epithelial differentiation mechanism. Therefore, SRSF6 may be upregulated in
prostate cancer [44].
EIF4G2 gene, Eukaryotic Translation Initiation Factor 4 Gamma 2 is a cap -
binding protein complex which has three sub units – eiF4A, eiF4E eiF4G. The gene is
known to upregulate p21, a cyclin dependant kinase inhibitor and interleukin 6 [46]. Higher
expression levels of p21 oncogene protein are found with increasing prostate cancer tumor
grade [47]. Interleukin 6 is involved in the progression of prostate cancer [48], and is used
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as a clinicopathological feature by detecting the levels in serum [49]. With the upregulated
expression levels of EIF4G2 gene in prostate cancer, it can be used as a potential marker
for studying the progression of the disease.
Interestingly, EIF4G2 and HLA-DMB which are part of the gene set that can
identify right side from the rest, they are both part of Allograft rejection SuperPath path-
way [50].
The discovery of fusion protein transcripts in the recent times have helped study-
ing prostate cancer development with much detail. ALG5, Dolichyl-Phosphate Beta-
Glucosyltransferase and PIGU, Phosphatidylinositol Glycan Anchor Biosynthesis Class
forms a chimeric-fusion protein transcript in which glucosyltransferase, the head from
ALG5 is retained but GPI transamidase, the tail has been eliminated in PIGU resulting
in the loss of functionality of both the genes [51]. The uncommon joining of the genes
would result in serious complications in the overall environment of the cell causing fur-
ther progression of the cancer. The transcription of the fused ALG5-PIGU is androgen
independent [52]. Fusion protein transcripts will serve as an important biomarker both in
detection and treatment of Prostate Cancer.
SNAI2, Snail Family Transcriptional Repressor 2 encodes zinc-finger protein of
the Snail family transcription factors, is involved in the generation and migration of neu-
ral crest cells in embryonic stages which is driven by epithelial to mesenchymal transition
(EMT). Presence of neuroendocrine cells in nests - neuroendocrine differentiation (NED)
is a known histological marker for prostate Cancer. SNAI2 expression is down regulated
in prostate cancer and silencing of the gene may turn on neuroendocrine differentiation,
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pluripotent genes and turn on specific metastasis suppressors [53]. SNAI2 knockdown ini-
tiating metastatic suppressor genes involves many pathways and further research is needed
to derive a conclusion. Studies of SNAI2 gene regulation properties will help us in under-
standing the development of prostate cancer.
MRI1, Methylthioribose-1-Phosphate Isomerase 1 gene helps in catalyses of me-
thionine, an important amino acid, in methionine salvage pathway. Development of cer-
tain cancers like prostate, glioma, bladder, breast, melanoma are dependent on methionine
[54, 55]. To understand the dependency of methionine in prostate cancer a study has been
conducted on patients who were not receiving any conventional treatment and were under-
going an intensive lifestyle program with a restricted methionine vegan diet. Analysis of
serum samples revealed that there was a 70% inhibition of the growth androgen sensitive
prostate adenocarcinoma (LNCaP) cells [56]. The data suggests that methionine restricted
diet and lifestyle changes may help in slowing down the development of prostate cancer.
3.4 Conclusion
Understanding gene activity in the prostate cancer laterality may help to guide the diag-
nosis and treatment of the disease. In this work, we have proposed a machine learning
method that is capable of predicting with a high accuracy the tumor location in a cancer
infected prostate. As a result, we have found genes as indicators that can differentiate
the three locations of prostate cancer with high accuracy. The contributions of this study
are two-fold. The proposed machine learning system can be used as a protocol for other
types of cancer and other clinical problems in cancer studies. It also open the doors for
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potential biomarkers that can be further tested in wet-lab scenarios with the hope to move
to clinical trials in order to replace the invasive biopsy or inaccurate image scanning.
The literature shows strong relations between prostate cancer metastasis and the
computationally derived genes. Wet-lab experiments and RNA-seq profiling of those genes
will better explore the relation between the findings and the prostate cancer laterality,
which will potentially help the prognosis of the disease.
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Method to Identify Cancer
Biomarkers Based on Gene-Disease
Relations
4.1 Introduction
Next generation sequencing (NGS) is one of the most important technologies to explore
genetic associations in medical studies. NGS technologies large data sets, which provides a
detailed view of the human genome [1]. The sensitivity, speed and reduced cost per sample
make it an attractive option, especially when compared to older technologies. These details
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include the actual DNA or RNA in various forms. The amount of raw data produced require
many computational steps to produce high-quality data that can be later used to obtain
information [2]; this information can be in the form of mutations, copy number alterations
(CNA), and others. Cancer is known to be a genetic disorder which might be heritable
or in terms of somatic mutations. NGS has a significant impact on the detection, and
treatment of this disease [3].
The generated data sets from this technology are huge and involve a big chal-
lenge. Machine learning techniques, on the other hand, have proved to be useful for such
large data sets and provided excellent results for classifying cancer states based on gene ex-
pression, CNA levels or mutations of certain genes. Machine learning techniques construct
models that can be used to predict certain biological characteristics from multi-dimensional
data sets, these predictive models are becoming essential to modern biological research [4]
[5]. Machine learning offers so many techniques that can be used to extract information
from these data sets. The data sets are made of a huge number of genes or transcripts
expressions. These gene/transcripts are called attributes in machine learning. One of the
first steps in machine learning is to reduce the number of attributes. In a typical data-set
that contains gene expressions, the number of attributes is approximately 35,000 to 40,000
genes, and can reach up to 65,000 transcripts. The reduction is done using a procedure
called feature selection [6], in which the attributes that do not affect the performance of
the model are removed.
Feature selection is done usually in two steps. The first step is to give a score
for each attribute against the medical feature that the model tries to predict. This step
is called filter-based feature selection. The second step is to find sets of attributes that
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can be used together to classify a certain clinical sign, this step is called wrapper-based
feature selection. The classifiers usually provide a model that can classify a certain clinical
sign [7]. For example a certain Gleason score in prostate cancer or a certain breast cancer
stage. The produced model can be evaluated using certain measures, for e.g. accuracy,
specificity or Area Under the Curve (AUC) [8].
The last step would require an expert to look into the findings and to search the
latest literature to verify the results. Hamzeh et al. applied a method to identify biomarkers
that can predict Gleason score stages for prostate cancer patients using machine learning
techniques [9]. Gleason score is a grading system which is widely used to describe the
aggressiveness of prostate cancer, it was first introduced by Dr. Donald Gleason back in
the 1960’s. A recent study proposed to join certain Gleason scores together, which will
create a new 5 Grade Group system, this simplifies the Gleason score[10]. Disease to gene
relation is a field that has been studied widely, and the findings have been published in
medical journals and scientific papers. In this regard, DisGeNET [11] is a database that
collects such knowledge and provides a tool that can be queried to find proven relations
between diseases and genes. In this work, we integrate the latest knowledge from the
literature as a step in the feature selection method. The results show an increase in the
number and relevance of cancer related genes that can be used in a predictive model.
DisGeNET integrates data from expert-curated repositories, GWAS catalogues,
animal models and the literature. DisGeNET data are homogeneously annotated with
controlled vocabularies and community-driven ontologies. DisGeNET utilizes the follow-
ing resources to provide the disease to gene relations: The Comparative Toxicogenomics
Database (CTD) [12], UniProt [13], ClinVar [14], Orphanet [15], The GWAS Catalog [16],
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The Rat Genome Database (RGD) [17], The Mouse Genome Database (MGD) [18], and
The Genetic Association Database (GAD) [19]. It also incorporates the literature directly
using text-mining approaches like The Literature Human Gene Derived Network (LHGDN)
[20] and BeFree data, obtained using the BeFree System, which extracts gene-disease as-
sociations from MEDLINE abstracts [21] [22].
This database provides many ways to collect its findings, either through the main
Web portal, a Web API, a SQL database or an all in one file. The results would be a score
that relates a gene to disease.
We are proposing a new machine learning pipeline that utilizes proven literature
knowledge to identify bio-markers that can be used to classify certain clinical attributes.
4.2 Methods
The proposed machine learning method starts with a basic data pre-procession step fol-
lowed by two different filter-based feature selection methods. The output of the two meth-
ods are two different lists, each one includes the gene names that affect the actual class.
We then create a new list from the combination of the two lists and create a third list from
the intersection of the two lists. The combined version is sent to DisGeNET to obtain
the scores against the actual disease that we are looking for, and the intersection list is
processed in another function that checks Pearson’s correlation [26] among the different
genes depending on their expression levels. The two methods produce different scores for
each gene. The final score for all the genes is calculated, and then sorted in a descending
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Figure 4.1: Machine learning pipeline used on the proposed method and testing.
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order according to the final score. A wrapper-based filter selection method picks the top
N number of genes in the list and tries to find the best subset with the best classifier
according to their ROC. After this step, the wrapper-based feature selection picks a larger
N to find another subset and calculates the ROC for the new subset and the new classifier.
This process continues until all the genes in the sorted final list are considered. We then
pick the best subset based on ROC and relations to the disease that we are looking for, as
the first generated subset will have genes that are more related to the given disease. Thus,
the final choice would be specific to each researcher. Figure 4.1 illustrates the machine
learning pipeline used by the proposed method. The details of each step are explained
below.
4.2.1 Pre-processing
This step checks for missing data and fills the missing cells with the median values. In
the same step, we also look for attributes whose values are not changing throughout the
samples. These attributes are usually irrelevant for the model, and so they are deleted at
this stage. A specific step that is needed for DisGeNET makes sure that the gene names
are actually following the HGNC [23] naming schema. If the gene names correspond to
the Ensembl genes naming codes [24], an actual name converter is used to convert these
into the HGNC. If the data-set includes transcript names, they need to be converted to the
HGNC naming schema, and again the developed converter applied the required conversion.
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4.2.2 Filter-based feature selection
As the data for gene expressions, CNA or mutation are numerical and continuous, a good
filter-based scoring criterion is Information Gain (IG) [25].
We used IG to rank all the attribute with a score that relates to the highest
information gain against the different classes of choice.
IG of feature X with respect to class Y is calculated as follows:
IG(Y,X) = H(Y )−H(Y |X), (4.1)
Here, H(Y ) is the entropy of class Y , H(Y |X) is the conditional entropy of Y
given X, p(y) is the probability of y, p(x) is the probability of x and p(y|x) is the probability
of y given x.
After obtaining the scores for each attribute using IG, we save the names of the
gene with scores higher than zero in a list.
We also use another filter based method, Chi-squared which measures the degree
of independence of each feature:
χ2(Y,X) =
N × (AD − CB)2
(A+ C)× (B +D)× (A+B)× (C +D)
(4.2)
where A is the number of times feature X and class Y co occur, B in the number
of times X occurs without Y , C in the number of times Y occurs without X , D in the
number of times neither X and Y occurs, and N is the total number of samples.
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We run Chi-squared on the original data to generate another list that contains
the gene name with scores higher than zero in a list. The two lists are combined into a
new combined list that includes all the gene names that have a positive score from each of
the methods. Another list is created from the intersection of the two lists.
The intersection list is used in a Pearson’s correlation test, which is a statistical
method that finds the correlation between two genes based on their expression levels as
follows:




where cov is the co-variance between X and Y , σx is the standard deviation of
x, and σy is the standard deviation of y.
4.2.3 DisGeNET
The combined list that is generated in the filter based feature selections step is used during
this step. We noticed that using the online API version of DisGeNET to query each
gene in the list against the given diseases did not work well as the number of genes was
more than 5,000 genes and it took a very long time to query each gene. We used the
offline Command Separated Values (CSV) version, which provides instant responses to
each query. DisGeNET provides a single score against each query, the query itself requires
the gene name in HGNC gene naming schema and requires the disease name. As in real
life, when an expert verifies the biomarkers, they usually check if the gene is related to a
particular disease (specific cancer type or stage). They also check if the gene is related to
cancer in general. As such, we had to do the same, each gene will be DisGeNET is queried
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twice for each gene. The first query includes the gene name and the particular cancer type
we are looking for, while the second query includes the gene name and the word ”cancer”.
Our method utilizes RegEx [27] to find any disease name that includes the word ”cancer”.
This means that each gene has two scores from each query. We give the specific cancer
score a high weight δ and the score returned for cancer a lower weight γ. Thus, the total
score for the gene is:
s(X) = s(a) ∗ δ + s(b) ∗ γ + s(c) ∗ β (4.4)
where s(x) is the final score, s(a) is the score returned for the specific cancer
type, s(b) is the score returned for the word ”cancer”, s(c) is the score obtained from the
Pearson correlation, δ, γ, β are user-defined weights.
δ, γ, β are weights defined by the researcher depending on the actual use of the
method itself, increasing the value of δ will prioritize genes that are related to the specific
key-word given, while increasing the value of γ will increase the priority of genes that are
known to be related to cancer in general, and increasing the value of β will increase the
priority of genes that are correlated based on their gene expression values.
A new data set is generated from the set of genes that are part of the final
calculated score, this list is sorted in descending order based on the calculated score.
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4.2.4 Wrapper-based feature selection
We choose the top N genes from the previously scored and sorted list to start this step. We
use a wrapper-based feature selection method that utilizes the minimum redundancy max-
imum relevance (mRMR) method. This method fuses feature selection and a classification
method to find a subset that can classify with high accuracy and specificity. This produces
a good AUC. It does this by taking features that contain minimum redundancy while at
the same time have a high correlation to the classification variable [28]. The equation for














where S is the set of features, I(i, j) is mutual information between features (i, j), and h
is the class.
In this step, we make sure to use multiple classifiers, since it is not guaranteed that
a specific classifier would perform on all data sets. The classifiers that were used during
this step are: Support Vector Machine with the Radial Basis Function kernel (SVB-RBF)
[29], Naive Bayes [30], Random Forest [31] and K-Nearest Neighbour [32].
The output of this step would be a single subset generated with each of the four
classifiers, and each one will have its own accuracy, specificity, and ROC.
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4.2.5 Back-propagation
In this step, we go back to the wrapper-based feature selection step and choose a larger
value for N and repeat the last wrapper-based feature selection method again to generate
another subset for each of the classifiers, the results are saved for each value of N . We
continue doing this until the value of N is equal to the number of genes in the scored list.
By the end of this final step, we will have scores from each of the four classifiers
for each of the values of N used. The final decision on which subset and classifier to choose
can be automated based on the larger value of the AUC and the smallest value of N used.
Instead, the researcher can pick which set of genes to choose. Taking into considerations,
that the lower number of N means that genes are most likely related to the given key-word
and that provide genes that are related to the clinical attributes in study.
4.3 Results and Discussion
In our previous work [9], an RNA-Seq data set of 104 prostate cancer patients was analyzed.
This data set is publicly available from the National Center for Biotechnology Information
(NCBI) with Gene Expression Omnibus (GEO) number GSE54460 [33]. It includes samples
with different Gleason stages, and has been analyzed using machine learning techniques to
identify transcripts that are linked to prostate progression.
In that study, filter-based feature selection is performed first using IG. Then,
a wrapper-based feature selection was performed on the resulting genes to find the best
possible subset that are able to predict the Gleason score group with the highest accuracy
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possible. After the subset is identified for each of the Gleason score, an expert has to take
revise the genes that were used to classify each stage and look into the literature for a
proof that these genes are already linked to prostate cancer or at least related to types
of cancer. The expert found that only seven out of the 26 genes that we identified were
already found in the literature. We applied the new method on the same data set.
We started with the pre-processing step, and noticed that the transcripts were
used in this data set. These needed to be converted to the NHGC naming schema. We
then ran the two filter-based feature selection methods and identified the combined list and
the intersected list. The combined list was processed with the DigGeNET and the scores
for each gene were calculated. The other intersected list was processed with Pearson’s
correlation test and the final scores for each gene were calculated. The genes were sorted
in descending order based on their score.
We then picked N = 500 to start the wrapper-based feature selection with the
top 500 genes. Wrapper-based feature selection provided a different subset for each of the
four classifiers used. We then started increasing N by 500 genes each time and continued
repeating the wrapper-based feature selection step with the a new value of N , until all the
genes in the sorted list were used. With the new method, we were able to obtain similar
results to the original method. The results for the original method are shown in Table 4.3,
and the results for the new method are shown in Table 4.5.
The results shown in Table 4.5 are for N = 500. We were able to classify with
high accuracy using a subset of 21 genes, 20 of these genes are already known to be related
to prostate cancer directly, or to another type of cancer. Increasing the value of N increased
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the accuracy for the ’347 vs rest’, but the number of genes related to cancer went down to
the original number that was discovered in the first study.
The accuracy for the rest of the Gleason scores did not increase as it is already
very high. We can notice in Table 3 how the accuracy of the class ’347 vs rest’ increased
while the number of genes related to cancer becomes smaller.
Table 4.1: Results for running the laterality study.
Total/Average 347 vs rest 437 vs rest 336 vs rest 448 vs 538
Accuracy 98 94 98 100 100
Number of Genes 26 15 7 3 1
Cancer related 7 3 2 1 1
Table 4.2: Results for running the laterality study with the new proposed method
Total/Average 347 vs rest 437 vs rest 336 vs rest 448 vs 538
Accuracy 98 94 98 100 100
Number of genes 26 15 7 3 1
Cancer related 7 3 2 1 1
Table 4.3: Results for running the previous method.
Total/Average 347 vs rest 437 vs rest 336 vs rest 448 vs 538
Accuracy 98 94 98 100 100
Number of genes 26 15 7 3 1
Cancer related 7 3 2 1 1
4.4 Conclusion
Using feature selection is an important step in any machine learning problem that has a
large number of attributes. In the field of biology and especially studying gene expression,
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Table 4.4: Results for running the proposed method.
Total/Average 347 vs rest 437 vs rest 336 vs rest 448 vs 538
Accuracy 95 83 98 100 100
Number of genes 21 7 8 4 2
Cancer related 20 7 8 3 2
Table 4.5: The effect of changing the value of (number of genes chosen) on the classification
performance and the number of genes that are related to cancer.
N Classification accuracy Number of genes Cancer related
500 83 7 7
1000 86 10 6
1500 90 10 5
2000 93 13 4
2500 94 15 3
the number of features is huge, and many of the features/genes that are eliminated during
this step might be a gene that is proven to be related to cancer that is being studied or
to another related cancer type. With the new method, genes that are proven in literature
are priority and are part of the first phase of the wrapper-based feature selection step. In
fact, they are part of each step after the selection. At the same time, if a gene is not at all
expressed, or if it is not deferentially expressed, it is discarded at the first pre-processing
step. The results for each iteration in the last step are stored, so that the researcher is able
to choose which sub set has either a larger AUC or that the subset that has the highest
number of genes related to cancer.
We are planning to incorporate deep learning into future versions of this method,
either as an additional feature selection step, or as another classifier within the wrapper-
base feature selection step.
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Future versions of this method are expected to integrate deep learning
techniques. This will be done either as a supplementary feature selection step or as an
additional classifier within the wrapper-based feature selection step.
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Chapter 5
Conclusion and Future Work
5.1 Conclusion
The main contribution of this thesis is to provide a generic pipeline for modeling RNA-
Seq data as a supervised learning scheme used to obtain meaningful biomarkers in cancer.
While the main models were created for different cancer problems, the proposed models
showed high performance and throughput. In Chapter 2, the proposed models we were
able to extract transcriptomic biomarkers that can predict, with very high accuracy, cer-
tain Gleason groups for prostate cancer. Using the model described in Chapter 3, we
were able to detect prostate cancer location based on the gene expressions provided. Ad-
ditionally, we performed biological validation using the literature in collaboration with
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biologists to investigate the obtained biomarkers’ significance. In Chapter 4, we proposed
a machine learning framework that is capable of enhancing conventional models to iden-
tify and validate biomarkers. This framework enhances the feature selection method by
utilizing knowledge extracted from Medline and other public resources. The method can
be used in any kind of cancer and can also be used as an integrative multi-omics model
that utilizes mutations, copy number alterations or any other clinical data that is avail-
able. The methods were able to provide a number of genes, which can be used to classify
samples accurately, and these genes are already proven to be related to cancer by the latest
literature.
The main methods proposed were able to handle different machine learning prob-
lems, such as class-imbalance and multi-class classification. In the work presented in Chap-
ter 3, we faced the the class-imbalance problem, in which the number of samples from one
class is much higher than the number of samples from the other class. We were able to
solve this problem using a combination of machine learning techniques.
To summarize, the contributions of this thesis are listed below:
⇒ Developing a framework that enhances the feature selection method for a classifica-
tion problem, and applying this method to enhance earlier work.
⇒ Proposing a machine learning pipeline that takes raw RNA-Seq data and provides a
number of biomarkers that can classify prostate cancer Gleason groups.
⇒ Developing a machine learning pipeline that takes gene expressions and provides a
model that detects the location of the prostate cancer.
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⇒ Handling the multi-class problem using the one-versus-all approach for prostate can-
cer Gleason stages.
⇒ Proposing a generic pipeline that can be proved to work with any kind of cancer, as
long as gene expressions or other types of data are used.
Even the though the proposed work is valuable, it does have some limitations.
The framework proposed in Chapter 4 provides excellent results, but it is sensitive to the
availability of information on the knowledge-base used. For example, if the gene name is
not in the database, then that gene will have the same priority as the genes that are not
related to cancer. Although this is an issue that is beyond our control, it is something that
could be investigated further. The proposed framework takes a long time to run, especially
when it creates the weights, though this task is performed only once at the beginning of
the pipeline. To solve the class-imbalance problem faced in Chapter 3, we used machine
learning techniques to create synthetic samples, which solves the class imbalance, while it
introduces extra samples that are not in the original sample set.
Most parts of this work have been published in conferences in collaboration with
my lab mates and other researchers from different disciplines, who have jointly co-authored
these publications. Chapter 2 has been published, by invitation, in Diagnostics journal as
part of the Special Issue on Next Generation Sequencing in Tumor Diagnosis and Treat-
ment, in 2019. Chapter 2 was also presented at the 5th International Work-Conference on
Bioinformatics and Biomedical Engineering, IWBBIO 2017, Granada, Spain, April 26–28,
2017. Chapter 3 has been accepted in a special edition of BMC Bioinformatics journal,
and is currently in press. This publication was the result of an invitation to submit an
96
extended version after presenting our work at the 6th International Work-Conference on
Bioinformatics and Biomedical Engineering, IWBBIO 2018, Granada, Spain, April 25–27,
2018., which was presented by L. Rueda as a keynote talk. Chapter 4 of this thesis was
presented at the Machine Learning Models for Multi-omics Data Integration, MODI 2019,
a workshop held at the 10th ACM Conference on Bioinformatics, Computational Biology,
and Health Informatics (ACM-BCB), in the , Niagara Falls, New York, September 7-10,
2019., in which we received an invitation to submit an extended version to a special col-
lection of Evolutionary Bioinformatics journal. The draft has been submitted already and
is currently being reviewed.
5.2 Future work
Even though this work provides the scientific community with meaningful contributions,
there is some room for improvement.
• In Chapter 2, the hierarchical model utilized one-versus-all approach, which can be
enhanced by implementing other methods such as one-versus-rest and then a com-
parison can be done against the original results to provide a comprehensive solution
to the multi-class problem.
• The method implemented in Chapter 2 can be utilized to study other kinds of cancer,
as long as we utilize gene expressions or transcriptomic data.
• In Chapter 3, we utilized SMOTE to introduce synthetic samples to the minority class
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and we used NCL to remove samples from the majority class, a future enhancement
would add boosting and bagging methods and then benchmark the two methods.
• In the framework introduced in Chapter 4 we used the DisGeNET database. However,
other resources are available, accordingly, the framework can be enhanced by utilizing
plugins. These plugins can be used to connect the framework to any source that can




Information about data sets used
A.1 List of aligning percentage from 104 samples in
the Hierarchical method
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Table A.1: The percentage of uniquely aligned mapped reads to the human genome for
each sample of the 104 prostate cancer patients sample using the STAR genome alignment
tool.
SRA Sample Run name Gleason score Pstage Uniquely mapped reads
SRS554892 SRR1164787 347 pT3 91.20%
SRS554893 SRR1164788 336 pT2 89.76%
SRS554894 SRR1164789 336 pT2 89.01%
SRS554895 SRR1164790 347 pT3 88.81%
SRS554896 SRR1164791 347 pT2 88.27%
SRS554897 SRR1164792 347 pT2 89.32%
SRS554898 SRR1164793 437 pT1C 86.10%
SRS554899 SRR1164794 347 pT2 94.36%
SRS554900 SRR1164795 448 pT2B 93.49%
SRS554901 SRR1164796 336 pT1C 94.33%
SRS554902 SRR1164797 347 pT1C 92.03%
SRS554903 SRR1164798 347 pT2C 94.88%
SRS554904 SRR1164799 347 pT2 92.58%
SRS554905 SRR1164800 437 pT2C 91.19%
SRS554906 SRR1164801 538 pT3A 93.76%
SRS554907 SRR1164802 347 pT2A 93.75%
SRS554908 SRR1164803 347 pT3A 93.33%
SRS554909 SRR1164804 347 pT2C 93.91%
Continued on next page –
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SRA Sample Run name Gleason score Pstage Uniquely mapped reads
SRS554910 SRR1164805 336 pT2C 92.92%
SRS554911 SRR1164806 347 pT2C 92.77%
SRS554912 SRR1164807 437 pT2C 92.28%
SRS554913 SRR1164808 448 pT2C 91.58%
SRS554914 SRR1164809 347 pT2C 95.75%
SRS554915 SRR1164810 347 pT2A 93.42%
SRS554916 SRR1164811 347 pT2C 96.01%
SRS554917 SRR1164812 347 pT2 90.93%
SRS554918 SRR1164813 347 pT2 95.03%
SRS554919 SRR1164814 347 pT2A 95.59%
SRS554920 SRR1164815 437 pT2C 94.04%
SRS554921 SRR1164816 347 pT2C 92.04%
SRS554922 SRR1164817 347 pT3A 92.72%
SRS554923 SRR1164818 347 pT3A 92.92%
SRS554924 SRR1164819 347 pT2C 93.50%
SRS554925 SRR1164820 347 pT2C 91.91%
SRS554926 SRR1164821 336 pT2A 89.54%
SRS554927 SRR1164822 347 pT2A 92.63%
SRS554928 SRR1164823 437 pT2B 93.39%
Continued on next page –
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SRA Sample Run name Gleason score Pstage Uniquely mapped reads
SRS554929 SRR1164824 437 pT2C 93.42%
SRS554930 SRR1164825 347 pT2C 90.71%
SRS554931 SRR1164826 437 pT2A 93.48%
SRS554932 SRR1164827 347 pT2C 88.83%
SRS554933 SRR1164828 347 pT2A 94.77%
SRS554934 SRR1164829 347 pT2C 94.67%
SRS554935 SRR1164830 336 pT2A 95.70%
SRS554936 SRR1164831 347 pT2A 95.32%
SRS554937 SRR1164832 347 pT2B 93.33%
SRS554938 SRR1164833 347 pT2C 91.23%
SRS554939 SRR1164834 437 pT2 94.51%
SRS554940 SRR1164835 347 pT2C 93.33%
SRS554941 SRR1164836 347 pT2A 95.19%
SRS554942 SRR1164837 336 pT2A 94.06%
SRS554943 SRR1164838 336 pT1C 88.71%
SRS554944 SRR1164839 336 pT1C 91.35%
SRS554945 SRR1164840 325 NA 89.48%
SRS554946 SRR1164841 549 pT1C 85.01%
SRS554947 SRR1164842 549 pT1C 87.16%
Continued on next page –
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SRA Sample Run name Gleason score Pstage Uniquely mapped reads
SRS554948 SRR1164843 347 pT2B 84.12%
SRS554949 SRR1164844 347 pT2B 85.67%
SRS554950 SRR1164845 437 pT2A 82.92%
SRS554951 SRR1164846 437 pT2A 88.31%
SRS554952 SRR1164847 437 pT1C 83.87%
SRS554953 SRR1164848 437 pT1C 87.38%
SRS554954 SRR1164849 347 pT2A 83.11%
SRS554955 SRR1164850 347 pT2A 85.12%
SRS554956 SRR1164851 347 pT2B 91.79%
SRS554957 SRR1164852 347 pT2B 92.70%
SRS554958 SRR1164853 347 pT1C 89.31%
SRS554959 SRR1164854 347 pT2B 92.03%
SRS554960 SRR1164855 336 pT1C 91.27%
SRS554961 SRR1164856 347 pT2A 81.47%
SRS554962 SRR1164857 459 pT2B 87.48%
SRS554963 SRR1164858 448 pT3B 84.01%
SRS554964 SRR1164859 437 pT2A 88.89%
SRS554965 SRR1164860 549 pT2B 94.46%
SRS554966 SRR1164861 347 pT1C 88.21%
Continued on next page –
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SRA Sample Run name Gleason score Pstage Uniquely mapped reads
SRS554967 SRR1164862 347 pT2A 89.46%
SRS554968 SRR1164863 437 pT3B 88.21%
SRS554969 SRR1164864 437 pT3B 93.94%
SRS554970 SRR1164865 437 pT2A 94.90%
SRS554971 SRR1164866 347 pT2A 85.55%
SRS554972 SRR1164867 448 pT3B 93.78%
SRS554973 SRR1164868 347 pT2A 91.84%
SRS554974 SRR1164869 347 pT1C 92.50%
SRS554975 SRR1164870 437 pT2A 92.78%
SRS554976 SRR1164871 437 pT1C 90.55%
SRS554977 SRR1164872 437 pT3B 95.48%
SRS554978 SRR1164873 347 pT2C 89.17%
SRS554979 SRR1164874 437 pT3A 89.97%
SRS554980 SRR1164875 437 pT2C 94.34%
SRS554981 SRR1164876 448 pT3B 88.91%
SRS554982 SRR1164877 459 pT3B 92.32%
SRS554983 SRR1164878 448 pT3B 94.09%
SRS554984 SRR1164879 347 pT3B 95.13%
SRS554985 SRR1164880 448 pT2C 93.98%
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SRS554986 SRR1164881 347 pT2C 91.91%
SRS554987 SRR1164882 437 pT2 94.01%
SRS554988 SRR1164883 448 pT2C 95.41%
SRS554989 SRR1164884 347 pT2C 91.62%
SRS554990 SRR1164885 347 pT2C 95.20%
SRS554991 SRR1164886 347 pT2C 90.21%
SRS554992 SRR1164887 347 pT4 91.75%
SRS554993 SRR1164888 437 pT2C 89.09%
SRS554994 SRR1164889 437 pT2C 87.34%
SRS554995 SRR1164890 347 pT2C 86.01%
SRS554996 SRR1164891 448 pT2A 90.54%
SRS554997 SRR1164892 347 pT3A 94.43%
A.2 List of samples used in the Laterality method
Table A.2: The location of tumor and the Gleason scores for the 499 prostate cancer
patients samples.
Sample name Gleason Prim. Gleason Sec. Gleason Score Laterality
TCGA-2A-A8VO 4 5 9 Bilateral
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TCGA-2A-A8VT 3 3 6 Bilateral
TCGA-2A-A8VV 4 4 8 Right
TCGA-2A-A8VX 4 3 7 Bilateral
TCGA-2A-A8W1 4 5 9 Left
TCGA-2A-A8W3 3 4 7 Left
TCGA-2A-AAYF 3 3 6 Right
TCGA-2A-AAYO 3 3 6 Bilateral
TCGA-2A-AAYU 4 4 8 Left
TCGA-4L-AA1F 4 3 7 Bilateral
TCGA-CH-5737 3 3 6 Bilateral
TCGA-CH-5738 3 4 7 Bilateral
TCGA-CH-5739 3 4 7 Left
TCGA-CH-5740 4 5 9 Bilateral
TCGA-CH-5741 3 4 7 Bilateral
TCGA-CH-5743 4 3 7 Bilateral
TCGA-CH-5744 3 4 7 Bilateral
TCGA-CH-5745 3 4 7 [Not Available]
TCGA-CH-5746 4 3 7 Bilateral
TCGA-CH-5748 3 4 7 Bilateral
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TCGA-CH-5750 5 5 10 Bilateral
TCGA-CH-5751 4 4 8 Bilateral
TCGA-CH-5752 4 5 9 Bilateral
TCGA-CH-5753 4 5 9 Bilateral
TCGA-CH-5754 5 4 9 Bilateral
TCGA-CH-5761 4 3 7 Left
TCGA-CH-5762 3 4 7 Bilateral
TCGA-CH-5763 4 3 7 Bilateral
TCGA-CH-5764 3 4 7 Bilateral
TCGA-CH-5765 4 3 7 Bilateral
TCGA-CH-5766 4 3 7 Bilateral
TCGA-CH-5767 2 4 6 Bilateral
TCGA-CH-5768 5 4 9 Bilateral
TCGA-CH-5769 4 3 7 Bilateral
TCGA-CH-5771 4 5 9 Bilateral
TCGA-CH-5772 4 3 7 Bilateral
TCGA-CH-5788 3 4 7 Bilateral
TCGA-CH-5789 3 4 7 Bilateral
TCGA-CH-5790 3 4 7 Bilateral
Continued on next page –
107
– continued from previous page
Sample name Gleason Prim. Gleason Sec. Gleason Score Laterality
TCGA-CH-5791 4 5 9 Bilateral
TCGA-CH-5792 3 4 7 Bilateral
TCGA-CH-5794 4 3 7 Bilateral
TCGA-EJ-5494 5 3 8 Bilateral
TCGA-EJ-5495 3 4 7 Bilateral
TCGA-EJ-5496 3 4 7 Bilateral
TCGA-EJ-5497 4 3 7 Bilateral
TCGA-EJ-5498 4 3 7 Bilateral
TCGA-EJ-5499 4 3 7 Bilateral
TCGA-EJ-5501 4 3 7 Bilateral
TCGA-EJ-5502 5 3 8 Bilateral
TCGA-EJ-5503 4 3 7 Bilateral
TCGA-EJ-5504 4 3 7 Bilateral
TCGA-EJ-5505 5 3 8 Bilateral
TCGA-EJ-5506 4 5 9 Bilateral
TCGA-EJ-5507 3 4 7 Bilateral
TCGA-EJ-5508 3 4 7 Bilateral
TCGA-EJ-5509 4 3 7 Bilateral
TCGA-EJ-5510 3 4 7 Bilateral
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TCGA-EJ-5511 3 4 7 Bilateral
TCGA-EJ-5512 4 5 9 Bilateral
TCGA-EJ-5514 3 4 7 Bilateral
TCGA-EJ-5515 3 4 7 Right
TCGA-EJ-5516 3 3 6 Bilateral
TCGA-EJ-5517 4 5 9 Bilateral
TCGA-EJ-5518 4 4 8 Bilateral
TCGA-EJ-5519 3 4 7 Bilateral
TCGA-EJ-5521 3 4 7 Right
TCGA-EJ-5522 4 5 9 Bilateral
TCGA-EJ-5524 4 5 9 Bilateral
TCGA-EJ-5525 4 4 8 Bilateral
TCGA-EJ-5526 4 3 7 Bilateral
TCGA-EJ-5527 3 4 7 Bilateral
TCGA-EJ-5530 4 3 7 Bilateral
TCGA-EJ-5531 3 4 7 Bilateral
TCGA-EJ-5532 3 4 7 Bilateral
TCGA-EJ-5542 4 3 7 Bilateral
TCGA-EJ-7115 3 4 7 Bilateral
Continued on next page –
109
– continued from previous page
Sample name Gleason Prim. Gleason Sec. Gleason Score Laterality
TCGA-EJ-7123 3 4 7 Bilateral
TCGA-EJ-7125 3 4 7 Bilateral
TCGA-EJ-7218 4 3 7 Bilateral
TCGA-EJ-7312 4 3 7 Bilateral
TCGA-EJ-7314 4 3 7 Bilateral
TCGA-EJ-7315 3 4 7 Bilateral
TCGA-EJ-7317 4 3 7 Bilateral
TCGA-EJ-7318 3 3 6 Bilateral
TCGA-EJ-7321 3 4 7 Bilateral
TCGA-EJ-7325 3 4 7 Bilateral
TCGA-EJ-7327 4 3 7 Bilateral
TCGA-EJ-7328 4 3 7 Bilateral
TCGA-EJ-7330 3 4 7 Bilateral
TCGA-EJ-7331 3 4 7 Bilateral
TCGA-EJ-7781 4 4 8 Bilateral
TCGA-EJ-7782 4 3 7 Bilateral
TCGA-EJ-7783 4 3 7 Bilateral
TCGA-EJ-7784 3 4 7 Bilateral
TCGA-EJ-7785 3 4 7 Bilateral
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TCGA-EJ-7786 3 4 7 Bilateral
TCGA-EJ-7788 4 3 7 Bilateral
TCGA-EJ-7789 3 4 7 Bilateral
TCGA-EJ-7791 3 4 7 Bilateral
TCGA-EJ-7792 3 4 7 Bilateral
TCGA-EJ-7793 3 4 7 Bilateral
TCGA-EJ-7794 3 4 7 Bilateral
TCGA-EJ-7797 4 4 8 Bilateral
TCGA-EJ-8468 4 5 9 Left
TCGA-EJ-8469 4 3 7 Bilateral
TCGA-EJ-8470 4 4 8 Bilateral
TCGA-EJ-8472 4 4 8 [Not Available]
TCGA-EJ-8474 4 4 8 Bilateral
TCGA-EJ-A46B 3 5 8 Bilateral
TCGA-EJ-A46D 4 4 8 Bilateral
TCGA-EJ-A46E 4 4 8 Bilateral
TCGA-EJ-A46F 4 4 8 Bilateral
TCGA-EJ-A46G 3 4 7 Bilateral
TCGA-EJ-A46H 3 4 7 Bilateral
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TCGA-EJ-A46I 4 5 9 Bilateral
TCGA-EJ-A65B 4 4 8 [Not Available]
TCGA-EJ-A65D 4 3 7 Bilateral
TCGA-EJ-A65E 4 5 9 Bilateral
TCGA-EJ-A65F 3 5 8 Bilateral
TCGA-EJ-A65G 4 5 9 Bilateral
TCGA-EJ-A65J 3 3 6 Bilateral
TCGA-EJ-A65M 4 4 8 Bilateral
TCGA-EJ-A6RA 4 3 7 Bilateral
TCGA-EJ-A6RC 3 4 7 Bilateral
TCGA-EJ-A7NF 3 4 7 Bilateral
TCGA-EJ-A7NG 3 4 7 Bilateral
TCGA-EJ-A7NH 4 4 8 Bilateral
TCGA-EJ-A7NJ 3 4 7 Bilateral
TCGA-EJ-A7NK 4 5 9 Bilateral
TCGA-EJ-A7NM 4 3 7 Bilateral
TCGA-EJ-A7NN 3 4 7 Bilateral
TCGA-EJ-A8FN 4 3 7 Bilateral
TCGA-EJ-A8FO 3 5 8 Bilateral
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TCGA-EJ-A8FP 3 4 7 Bilateral
TCGA-EJ-A8FS 5 3 8 Bilateral
TCGA-EJ-A8FU 3 3 6 Bilateral
TCGA-EJ-AB20 3 3 6 Bilateral
TCGA-EJ-AB27 4 3 7 Bilateral
TCGA-FC-7708 4 5 9 Bilateral
TCGA-FC-7961 5 3 8 Bilateral
TCGA-FC-A4JI 4 5 9 Bilateral
TCGA-FC-A5OB 4 3 7 Bilateral
TCGA-FC-A66V 4 3 7 Bilateral
TCGA-FC-A6HD 3 3 6 Bilateral
TCGA-FC-A8O0 3 4 7 Bilateral
TCGA-G9-6329 4 3 7 Bilateral
TCGA-G9-6332 4 3 7 Bilateral
TCGA-G9-6333 3 4 7 Bilateral
TCGA-G9-6336 4 3 7 Bilateral
TCGA-G9-6338 3 4 7 Bilateral
TCGA-G9-6339 3 3 6 Bilateral
TCGA-G9-6342 4 3 7 Bilateral
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TCGA-G9-6343 3 3 6 Bilateral
TCGA-G9-6347 3 4 7 Bilateral
TCGA-G9-6348 3 4 7 Bilateral
TCGA-G9-6351 3 4 7 Bilateral
TCGA-G9-6353 3 4 7 Bilateral
TCGA-G9-6354 4 5 9 Right
TCGA-G9-6356 3 4 7 Bilateral
TCGA-G9-6361 4 3 7 Bilateral
TCGA-G9-6362 4 3 7 Bilateral
TCGA-G9-6363 3 4 7 Bilateral
TCGA-G9-6364 3 4 7 Bilateral
TCGA-G9-6365 4 3 7 Bilateral
TCGA-G9-6366 4 5 9 Left
TCGA-G9-6367 4 3 7 Bilateral
TCGA-G9-6369 3 4 7 Bilateral
TCGA-G9-6370 3 3 6 Bilateral
TCGA-G9-6371 4 3 7 Bilateral
TCGA-G9-6373 3 4 7 Bilateral
TCGA-G9-6377 3 4 7 Bilateral
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TCGA-G9-6378 4 3 7 Bilateral
TCGA-G9-6379 3 4 7 Bilateral
TCGA-G9-6384 3 4 7 Bilateral
TCGA-G9-6385 4 3 7 Bilateral
TCGA-G9-6494 4 3 7 Bilateral
TCGA-G9-6496 3 4 7 Bilateral
TCGA-G9-6498 4 5 9 Bilateral
TCGA-G9-6499 3 3 6 Bilateral
TCGA-G9-7509 4 4 8 Bilateral
TCGA-G9-7510 3 4 7 Bilateral
TCGA-G9-7519 4 4 8 Bilateral
TCGA-G9-7521 3 4 7 Bilateral
TCGA-G9-7522 5 5 10 Bilateral
TCGA-G9-7523 4 3 7 Bilateral
TCGA-G9-7525 4 4 8 Bilateral
TCGA-G9-A9S0 4 4 8 Bilateral
TCGA-G9-A9S4 4 4 8 Bilateral
TCGA-G9-A9S7 3 4 7 Bilateral
TCGA-H9-7775 3 3 6 Right
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TCGA-H9-A6BX 3 4 7 Bilateral
TCGA-H9-A6BY 3 3 6 Bilateral
TCGA-HC-7075 3 3 6 Right
TCGA-HC-7077 3 4 7 Bilateral
TCGA-HC-7078 3 4 7 Bilateral
TCGA-HC-7079 3 4 7 Bilateral
TCGA-HC-7080 4 5 9 Right
TCGA-HC-7081 3 3 6 Bilateral
TCGA-HC-7209 3 4 7 Bilateral
TCGA-HC-7210 3 4 7 Right
TCGA-HC-7211 3 4 7 Bilateral
TCGA-HC-7212 4 5 9 Right
TCGA-HC-7213 3 4 7 Bilateral
TCGA-HC-7230 3 4 7 [Not Available]
TCGA-HC-7231 4 5 9 Bilateral
TCGA-HC-7232 4 3 7 Bilateral
TCGA-HC-7233 3 4 7 Left
TCGA-HC-7736 3 4 7 Bilateral
TCGA-HC-7737 3 4 7 Bilateral
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TCGA-HC-7738 3 4 7 Bilateral
TCGA-HC-7740 3 4 7 Bilateral
TCGA-HC-7742 4 3 7 Bilateral
TCGA-HC-7744 4 3 7 Bilateral
TCGA-HC-7745 3 4 7 Bilateral
TCGA-HC-7747 3 3 6 Right
TCGA-HC-7748 4 3 7 Right
TCGA-HC-7749 3 4 7 Left
TCGA-HC-7750 3 4 7 Bilateral
TCGA-HC-7752 4 3 7 Bilateral
TCGA-HC-7817 3 4 7 Bilateral
TCGA-HC-7818 4 4 8 Bilateral
TCGA-HC-7819 3 4 7 Bilateral
TCGA-HC-7820 4 4 8 Bilateral
TCGA-HC-7821 3 3 6 Bilateral
TCGA-HC-8213 4 3 7 Bilateral
TCGA-HC-8216 3 4 7 Right
TCGA-HC-8256 3 4 7 Bilateral
TCGA-HC-8257 3 3 6 Bilateral
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TCGA-HC-8258 3 3 6 Bilateral
TCGA-HC-8259 3 4 7 Left
TCGA-HC-8260 3 4 7 Bilateral
TCGA-HC-8261 4 4 8 Bilateral
TCGA-HC-8262 4 5 9 Bilateral
TCGA-HC-8264 3 5 8 Bilateral
TCGA-HC-8265 4 4 8 Bilateral
TCGA-HC-8266 4 4 8 Bilateral
TCGA-HC-A48F 5 4 9 Bilateral
TCGA-HC-A4ZV 4 5 9 Bilateral
TCGA-HC-A631 4 5 9 Bilateral
TCGA-HC-A632 3 4 7 Bilateral
TCGA-HC-A6AL 4 3 7 Bilateral
TCGA-HC-A6AN 4 3 7 Bilateral
TCGA-HC-A6AO 3 4 7 Bilateral
TCGA-HC-A6AP 3 4 7 Bilateral
TCGA-HC-A6AQ 3 4 7 Bilateral
TCGA-HC-A6AS 4 3 7 Right
TCGA-HC-A6HX 3 4 7 Bilateral
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TCGA-HC-A6HY 3 4 7 Bilateral
TCGA-HC-A76W 3 4 7 Bilateral
TCGA-HC-A76X 5 4 9 Bilateral
TCGA-HC-A8CY 3 4 7 Bilateral
TCGA-HC-A8D0 3 4 7 Left
TCGA-HC-A8D1 5 4 9 Bilateral
TCGA-HC-A9TE 5 4 9 Bilateral
TCGA-HC-A9TH 4 5 9 Bilateral
TCGA-HI-7168 3 4 7 Bilateral
TCGA-HI-7169 3 3 6 Bilateral
TCGA-HI-7170 5 4 9 Bilateral
TCGA-HI-7171 4 3 7 Bilateral
TCGA-J4-8198 3 4 7 Bilateral
TCGA-J4-8200 4 3 7 Bilateral
TCGA-J4-A67K 3 4 7 Bilateral
TCGA-J4-A67L 4 3 7 Left
TCGA-J4-A67M 3 4 7 Bilateral
TCGA-J4-A67N 3 4 7 Bilateral
TCGA-J4-A67O 3 3 6 Bilateral
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TCGA-J4-A67Q 4 3 7 Bilateral
TCGA-J4-A67R 3 4 7 Bilateral
TCGA-J4-A67S 3 4 7 Bilateral
TCGA-J4-A67T 4 4 8 Bilateral
TCGA-J4-A6G1 4 4 8 Bilateral
TCGA-J4-A6G3 3 4 7 Bilateral
TCGA-J4-A6M7 4 3 7 Bilateral
TCGA-J4-A83I 3 4 7 Bilateral
TCGA-J4-A83J 3 3 6 Bilateral
TCGA-J4-A83K 3 4 7 Bilateral
TCGA-J4-A83L 4 3 7 Bilateral
TCGA-J4-A83M 3 4 7 Bilateral
TCGA-J4-A83N 3 3 6 Bilateral
TCGA-J4-AATV 4 5 9 Bilateral
TCGA-J4-AATZ 3 3 6 Bilateral
TCGA-J4-AAU2 5 4 9 Bilateral
TCGA-J9-A52B 4 5 9 Bilateral
TCGA-J9-A52C 4 5 9 Bilateral
TCGA-J9-A52D 4 5 9 Bilateral
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TCGA-J9-A52E 4 5 9 Bilateral
TCGA-J9-A8CK 4 5 9 Bilateral
TCGA-J9-A8CL 5 4 9 Bilateral
TCGA-J9-A8CM 3 3 6 Bilateral
TCGA-J9-A8CN 4 3 7 Bilateral
TCGA-J9-A8CP 3 4 7 Bilateral
TCGA-KC-A4BL 3 4 7 Bilateral
TCGA-KC-A4BN 4 5 9 Right
TCGA-KC-A4BR 4 5 9 Bilateral
TCGA-KC-A4BV 3 4 7 Bilateral
TCGA-KC-A7F3 4 3 7 Bilateral
TCGA-KC-A7F5 3 4 7 Right
TCGA-KC-A7F6 3 4 7 Bilateral
TCGA-KC-A7FA 3 4 7 Bilateral
TCGA-KC-A7FD 3 4 7 Bilateral
TCGA-KC-A7FE 4 5 9 Bilateral
TCGA-KK-A59V 5 4 9 Bilateral
TCGA-KK-A59X 4 5 9 Bilateral
TCGA-KK-A59Y 4 3 7 Bilateral
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TCGA-KK-A59Z 4 5 9 Bilateral
TCGA-KK-A5A1 3 4 7 Bilateral
TCGA-KK-A6DY 4 5 9 Bilateral
TCGA-KK-A6E0 4 5 9 Right
TCGA-KK-A6E1 3 4 7 Bilateral
TCGA-KK-A6E2 3 4 7 Bilateral
TCGA-KK-A6E3 3 4 7 Bilateral
TCGA-KK-A6E4 4 3 7 Right
TCGA-KK-A6E5 4 5 9 Bilateral
TCGA-KK-A6E6 5 4 9 Bilateral
TCGA-KK-A6E7 4 5 9 Bilateral
TCGA-KK-A6E8 4 5 9 Bilateral
TCGA-KK-A7AP 4 3 7 Right
TCGA-KK-A7AQ 4 5 9 Bilateral
TCGA-KK-A7AU 3 4 7 Bilateral
TCGA-KK-A7AV 4 3 7 Bilateral
TCGA-KK-A7AW 4 3 7 Right
TCGA-KK-A7AY 4 3 7 Bilateral
TCGA-KK-A7AZ 4 5 9 Right
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TCGA-KK-A7B0 4 3 7 Bilateral
TCGA-KK-A7B1 4 5 9 Bilateral
TCGA-KK-A7B2 4 5 9 Left
TCGA-KK-A7B3 4 5 9 Bilateral
TCGA-KK-A7B4 4 3 7 Bilateral
TCGA-KK-A8I4 3 4 7 Left
TCGA-KK-A8I5 4 3 7 Right
TCGA-KK-A8I6 4 5 9 Bilateral
TCGA-KK-A8I7 4 5 9 Bilateral
TCGA-KK-A8I8 4 4 8 Bilateral
TCGA-KK-A8I9 4 5 9 Bilateral
TCGA-KK-A8IA 4 5 9 Bilateral
TCGA-KK-A8IB 4 5 9 Bilateral
TCGA-KK-A8IC 5 4 9 Bilateral
TCGA-KK-A8ID 4 3 7 Bilateral
TCGA-KK-A8IF 4 3 7 Bilateral
TCGA-KK-A8IG 4 3 7 Bilateral
TCGA-KK-A8IH 4 5 9 Bilateral
TCGA-KK-A8II 4 3 7 Bilateral
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TCGA-KK-A8IJ 4 5 9 Bilateral
TCGA-KK-A8IK 4 5 9 Bilateral
TCGA-KK-A8IL 4 3 7 Bilateral
TCGA-KK-A8IM 3 4 7 Bilateral
TCGA-M7-A71Y 4 3 7 Bilateral
TCGA-M7-A71Z 3 3 6 Right
TCGA-M7-A720 3 4 7 Bilateral
TCGA-M7-A721 4 4 8 Bilateral
TCGA-M7-A722 4 3 7 Bilateral
TCGA-M7-A723 4 4 8 Bilateral
TCGA-M7-A724 4 3 7 Right
TCGA-M7-A725 4 5 9 Bilateral
TCGA-MG-AAMC 3 4 7 [Not Available]
TCGA-QU-A6IL 3 4 7 Bilateral
TCGA-QU-A6IM 3 4 7 Left
TCGA-QU-A6IN 3 3 6 Bilateral
TCGA-QU-A6IO 3 3 6 Bilateral
TCGA-QU-A6IP 5 3 8 Right
TCGA-SU-A7E7 3 4 7 Right
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TCGA-TK-A8OK 4 3 7 Right
TCGA-TP-A8TT 4 3 7 Left
TCGA-TP-A8TV 3 3 6 Bilateral
TCGA-V1-A8MF 3 4 7 Bilateral
TCGA-V1-A8MG 3 3 6 Bilateral
TCGA-V1-A8MK 3 4 7 Bilateral
TCGA-V1-A8ML 4 3 7 Bilateral
TCGA-V1-A8MM 3 4 7 Bilateral
TCGA-V1-A8MU 3 4 7 Bilateral
TCGA-V1-A8WL 3 3 6 Bilateral
TCGA-V1-A8WN 3 3 6 Bilateral
TCGA-V1-A8WS 4 5 9 Bilateral
TCGA-V1-A8WV 4 5 9 Bilateral
TCGA-V1-A8WW 3 4 7 Bilateral
TCGA-V1-A8X3 5 4 9 Bilateral
TCGA-V1-A9O5 5 4 9 Bilateral
TCGA-V1-A9O7 3 5 8 Bilateral
TCGA-V1-A9O9 4 5 9 Bilateral
TCGA-V1-A9OA 3 3 6 Bilateral
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TCGA-V1-A9OF 4 4 8 Right
TCGA-V1-A9OH 5 4 9 Bilateral
TCGA-V1-A9OL 3 3 6 Bilateral
TCGA-V1-A9OQ 3 3 6 Bilateral
TCGA-V1-A9OT 3 5 8 Bilateral
TCGA-V1-A9OX 4 3 7 Bilateral
TCGA-V1-A9OY 5 4 9 Bilateral
TCGA-V1-A9Z7 5 4 9 Bilateral
TCGA-V1-A9Z8 4 5 9 Bilateral
TCGA-V1-A9Z9 4 5 9 Bilateral
TCGA-V1-A9ZG 4 5 9 Bilateral
TCGA-V1-A9ZI 4 4 8 Left
TCGA-V1-A9ZK 4 4 8 Bilateral
TCGA-V1-A9ZR 4 4 8 Bilateral
TCGA-VN-A88I 4 4 8 Bilateral
TCGA-VN-A88K 3 4 7 Bilateral
TCGA-VN-A88L 3 4 7 Bilateral
TCGA-VN-A88M 4 3 7 Bilateral
TCGA-VN-A88N 3 4 7 Bilateral
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TCGA-VN-A88O 3 4 7 Bilateral
TCGA-VN-A88P 4 4 8 Bilateral
TCGA-VN-A88Q 4 4 8 Bilateral
TCGA-VN-A88R 4 4 8 Bilateral
TCGA-VN-A943 5 3 8 Bilateral
TCGA-VP-A872 3 4 7 Bilateral
TCGA-VP-A875 3 5 8 Bilateral
TCGA-VP-A876 4 5 9 Bilateral
TCGA-VP-A878 4 5 9 Right
TCGA-VP-A879 4 4 8 Right
TCGA-VP-A87B 4 3 7 Bilateral
TCGA-VP-A87C 4 5 9 Bilateral
TCGA-VP-A87D 3 3 6 Bilateral
TCGA-VP-A87E 4 5 9 Bilateral
TCGA-VP-A87H 3 4 7 Bilateral
TCGA-VP-A87J 4 4 8 Bilateral
TCGA-VP-A87K 5 4 9 Bilateral
TCGA-VP-AA1N 4 4 8 Bilateral
TCGA-WW-A8ZI 4 5 9 Right
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TCGA-X4-A8KQ 3 4 7 Bilateral
TCGA-X4-A8KS 4 3 7 Bilateral
TCGA-XA-A8JR 3 4 7 Right
TCGA-XJ-A83F 4 3 7 Bilateral
TCGA-XJ-A83G 3 4 7 Bilateral
TCGA-XJ-A83H 5 4 9 [Not Available]
TCGA-XJ-A9DI 4 4 8 Right
TCGA-XJ-A9DK 3 3 6 Right
TCGA-XJ-A9DQ 5 4 9 Bilateral
TCGA-XJ-A9DX 4 4 8 Bilateral
TCGA-XK-AAIR 5 5 10 Bilateral
TCGA-XK-AAIV 5 4 9 Bilateral
TCGA-XK-AAIW 4 4 8 Bilateral
TCGA-XK-AAJ3 4 3 7 Bilateral
TCGA-XK-AAJA 4 3 7 Left
TCGA-XK-AAJP 4 3 7 Bilateral
TCGA-XK-AAJR 4 3 7 Bilateral
TCGA-XK-AAJT 4 3 7 Bilateral
TCGA-XK-AAJU 4 3 7 Bilateral
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TCGA-XK-AAK1 5 5 10 Bilateral
TCGA-XQ-A8TA 4 5 9 Bilateral
TCGA-XQ-A8TB 3 3 6 Right
TCGA-Y6-A8TL 4 4 8 Bilateral
TCGA-Y6-A9XI 5 4 9 Right
TCGA-YJ-A8SW 4 5 9 Bilateral
TCGA-YL-A8HJ 4 5 9 Bilateral
TCGA-YL-A8HK 4 5 9 Bilateral
TCGA-YL-A8HL 4 5 9 Bilateral
TCGA-YL-A8HM 4 3 7 Bilateral
TCGA-YL-A8HO 4 5 9 Bilateral
TCGA-YL-A8S8 4 5 9 Bilateral
TCGA-YL-A8S9 4 4 8 Bilateral
TCGA-YL-A8SA 4 5 9 Bilateral
TCGA-YL-A8SB 4 5 9 Bilateral
TCGA-YL-A8SC 4 3 7 Bilateral
TCGA-YL-A8SH 4 5 9 Bilateral
TCGA-YL-A8SI 4 5 9 Bilateral
TCGA-YL-A8SJ 4 5 9 Bilateral
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TCGA-YL-A8SK 4 4 8 Bilateral
TCGA-YL-A8SL 4 5 9 Bilateral
TCGA-YL-A8SO 4 5 9 Bilateral
TCGA-YL-A8SP 4 5 9 Bilateral
TCGA-YL-A8SQ 4 5 9 Bilateral
TCGA-YL-A8SR 4 5 9 Bilateral
TCGA-YL-A9WH 4 5 9 Bilateral
TCGA-YL-A9WI 4 4 8 Bilateral
TCGA-YL-A9WJ 4 5 9 Bilateral
TCGA-YL-A9WK 4 5 9 Bilateral
TCGA-YL-A9WL 4 5 9 Bilateral
TCGA-YL-A9WX 5 4 9 Bilateral
TCGA-YL-A9WY 4 5 9 Bilateral
TCGA-ZG-A8QW 3 3 6 Bilateral
TCGA-ZG-A8QX 5 4 9 Bilateral
TCGA-ZG-A8QY 4 5 9 Bilateral
TCGA-ZG-A8QZ 5 4 9 Bilateral
TCGA-ZG-A9KY 5 4 9 Bilateral
TCGA-ZG-A9L0 4 5 9 Bilateral
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TCGA-ZG-A9L1 4 5 9 Bilateral
TCGA-ZG-A9L2 5 4 9 [Not Available]
TCGA-ZG-A9L4 5 4 9 Bilateral
TCGA-ZG-A9L5 5 4 9 Bilateral
TCGA-ZG-A9L6 4 5 9 Bilateral
TCGA-ZG-A9L9 5 4 9 Bilateral
TCGA-ZG-A9LB 4 5 9 Right
TCGA-ZG-A9LM 5 4 9 Right
TCGA-ZG-A9LN 5 4 9 Bilateral
TCGA-ZG-A9LS 5 4 9 Bilateral
TCGA-ZG-A9LU 4 5 9 Bilateral
TCGA-ZG-A9LY 4 5 9 Bilateral
TCGA-ZG-A9LZ 5 4 9 Bilateral
TCGA-ZG-A9M4 5 4 9 Bilateral
TCGA-ZG-A9MC 5 4 9 Bilateral
TCGA-ZG-A9N3 5 4 9 Bilateral
TCGA-ZG-A9ND 5 4 9 Bilateral
TCGA-ZG-A9NI 3 3 6 Bilateral
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